CN110894209A - Smooth receptor ligand - Google Patents

Smooth receptor ligand Download PDF

Info

Publication number
CN110894209A
CN110894209A CN201811066683.5A CN201811066683A CN110894209A CN 110894209 A CN110894209 A CN 110894209A CN 201811066683 A CN201811066683 A CN 201811066683A CN 110894209 A CN110894209 A CN 110894209A
Authority
CN
China
Prior art keywords
cdcl
nmr
ppm
reaction
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811066683.5A
Other languages
Chinese (zh)
Inventor
陶厚朝
赵飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ShanghaiTech University
Original Assignee
ShanghaiTech University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ShanghaiTech University filed Critical ShanghaiTech University
Priority to CN201811066683.5A priority Critical patent/CN110894209A/en
Publication of CN110894209A publication Critical patent/CN110894209A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/3311—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group
    • C08G65/3314—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the field of biotechnology, in particular to a smooth receptor ligand. The invention provides a smooth receptor ligand or an isomer prodrug, solvate and pharmaceutically acceptable salt thereof, wherein the structural formula of the smooth receptor ligand is as follows: A-linker-B, wherein A is an extracellular domain ligand structure, and B is a transmembrane domain ligand structure; linker is a linear, smooth receptor inactive subunit. The novel double-headed small molecule ligand for the smooth receptor provided by the invention is combined with the crystal structure data of the smooth receptor, and a connector is introduced into a proper site of an ectodomain ligand and a transmembrane domain ligand to obtain a brand-new double-headed ligand small molecule, so that the interaction between the ligand and the receptor and the biological activity of the ligand are enhanced.

Description

Smooth receptor ligand
Technical Field
The invention relates to the field of biotechnology, in particular to a smooth receptor ligand.
Background
Smoothing receptors belong to the F family of G-protein-coupled receptors (GPCRs), whose dysfunction leads to birth defects. In the 50 s of the 20 th century, many born lambs were found to have only one eye in the western united states, and the first natural plant small molecule ligand Cyclopamine (Cyclopamine) for the smooth receptor was discovered through studies on this cyclopia. Functional regulation of smooth receptors is associated with the development of a range of cancers, and thus smooth receptors are important targets in drug development. Over the past few decades, a number of lead compound ligands have been discovered, with two small molecule drugs being marketed in 2015. However, resistance to drugs caused by the smooth receptor mutants rapidly develops, and further modification of existing drugs is urgently needed.
Disclosure of Invention
In view of the above-mentioned drawbacks of the prior art, it is an object of the present invention to provide a smoothing receptor ligand, which solves the problems of the prior art.
To achieve the above objects and other related objects, the present invention provides, in one aspect, a smoothing receptor ligand, or an isomer prodrug, solvate, or pharmaceutically acceptable salt thereof, wherein the smoothing receptor ligand has the structural formula:
A-linker-B
wherein A is an ectodomain ligand structure, and B is a transmembrane domain ligand structure;
linker is a linear, smooth receptor inactive subunit.
In some embodiments of the invention, the extracellular domain ligand structure is a steroid structure.
In some embodiments of the invention, a is selected from the group shown below:
Figure BDA0001798453550000011
wherein E is selected from H, -OH;
f is selected from linear C1-C20 aliphatic groups containing or not containing heteroatoms selected from N, S, P, O;
g is selected from linear C1-C20 alkyl or acyl with or without a heteroatom selected from N, S, P, O.
In some embodiments of the invention, A has a structure selected from the group consisting of 20- (S) -hydroxycholesterol, 22- (S) -azacholesterol, cyclopamine, cholesterol, lithocholic acid, and 20- (S) -hydroxy-24-alkynylcholesterol.
In some embodiments of the invention, a is selected from the group shown below:
Figure BDA0001798453550000021
in some embodiments of the invention, the transmembrane domain ligand structure may be an amide or imine-like structure containing multiple aliphatic rings, nitrogen-containing aliphatic rings, benzene rings, aza-aromatic ring systems.
In some embodiments of the invention, B is selected from the group shown below:
Figure BDA0001798453550000022
wherein J is selected from substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, substituted or unsubstituted pyridyl, substituted or unsubstituted cycloalkyl, wherein the substituents are each independently selected from alkyl, alkenyl, alkynyl, F, Cl, Br, I, nitro, amino, hydroxy, alkoxy, cycloalkyl, aryl, heteroaryl;
l is selected from hydrogen, alkyl and substituent groups are selected from-NR 'R' substituted or unsubstituted cycloalkyl, wherein R 'and R' are independently selected from C1-C6 alkyl;
m is selected from substituents selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, -CF3、-OCF3Substituted or unsubstituted aryl or heteroaryl of alkylsulfonyl.
In some embodiments of the invention, the structure of B is selected from SAG, LY2940680, GDC0449, LDE225, SANT1, SANT 2.
In some embodiments of the invention, B is selected from the group shown below:
Figure BDA0001798453550000031
in some embodiments of the invention, the linker is a polyethylene glycol oligomer having a triazole structure. In some embodiments of the invention, the linker has the following structural formula:
Figure BDA0001798453550000032
wherein m and n are independently selected from integers between 0 and 7.
In some embodiments of the invention, the smoothing receptor ligand is selected from the group consisting of the compounds shown below:
Figure BDA0001798453550000033
Figure BDA0001798453550000041
Figure BDA0001798453550000051
Figure BDA0001798453550000061
Figure BDA0001798453550000071
Figure BDA0001798453550000081
Figure BDA0001798453550000091
Figure BDA0001798453550000101
Figure BDA0001798453550000111
in another aspect, the invention provides the use of the smooth receptor ligand or its isomer, prodrug, solvate, pharmaceutically acceptable salt in the preparation of smooth receptor agonist, inhibitor or antagonist.
In another aspect, the invention provides a pharmaceutical composition comprising the smooth receptor ligand or its isomer, prodrug, solvate, pharmaceutically acceptable salt
Drawings
FIG. 1 is a schematic diagram showing the molecular orientation and spacing of extracellular domain ligands and transmembrane domain ligands confirmed by the crystal structure according to the present invention.
FIG. 2 shows a schematic representation of the simultaneous binding of two domains of the smooth receptor by the bipitch molecule of the present invention.
FIG. 3 shows a U-shaped curve of the activity of a series of double-headed molecules of the invention versus linker length.
Detailed Description
The inventor integrates the receptors of each binding domain of the smooth receptor together through a proper connector, can realize that the small molecule drug simultaneously binds two structural domains through the proximity effect, thereby enhancing the drug activity and realizing the design of the small molecule drug for avoiding drug resistance, and the invention is completed on the basis.
In one aspect, the present invention provides a smooth receptor ligand, or an isomer (e.g., enantiomer, diastereomer, geometric isomer, tautomer, rotamer, atropisomer, racemate, etc.), prodrug, solvate, or pharmaceutically acceptable salt thereof, having a formula:
A-linker-B
wherein A is an ectodomain ligand structure, and B is a transmembrane domain ligand structure;
linker is a linear, smooth receptor inactive subunit.
In the smoothing receptor ligands provided herein, a is an extracellular domain ligand structure, which generally refers to a molecular structure capable of recognizing and binding to the extracellular domain of a smoothing receptor, which may be specific. The ectodomain ligand structure may be an inhibitor structure, an antagonist structure, or an agonist structure. The ectodomain ligand structure may be a steroid structure, for example, a may be selected from the group shown below:
Figure BDA0001798453550000121
wherein E is selected from H (hydrogen atom), -OH (hydroxyl group); f is selected from C1-C20, C1-C12, C1-C6 and C1-C3 straight-chain aliphatic groups containing or not containing heteroatoms, and in the group F, the heteroatoms can be N, S, P, O; g is selected from C1-C20, C1-C12, C1-C6 and C1-C3 straight-chain alkyl or acyl containing or not containing heteroatoms, and in the group G, the heteroatoms can be N, S, P, O and the like. More specifically, the ectodomain ligand structure may be a group structure corresponding to, but not limited to, 20- (S) -hydroxycholesterol, 22- (S) -azacholesterol, cyclopamine, cholesterol, lithocholic acid, 20- (S) -hydroxy-24-alkynyl cholesterol, and other steroids, and the like. In other embodiments of the present invention, a may be selected from the group shown below:
Figure BDA0001798453550000122
in the ligand of the smooth receptor provided by the invention, B is a transmembrane domain ligand structure, and the transmembrane domain ligand structure generally refers to a molecular structure which can have recognition capacity on the transmembrane domain of the smooth receptor and can be combined with the transmembrane domain of the smooth receptor, and the recognition and the combination can be specific. The transmembrane domain ligand structure may be an inhibitor structure, an antagonist structure or an agonist structure. The transmembrane domain ligand structure can be an amide or imine structure containing a plurality of aliphatic rings, nitrogen-containing aliphatic rings, benzene rings and nitrogen-containing aromatic ring systems, for example, B can be selected from the following groups:
Figure BDA0001798453550000131
wherein J is selected from substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, substituted or unsubstituted pyridyl, and substituted or unsubstituted C3-C9 cycloalkyl, in the group J, the phenyl, benzyl, pyridyl and cycloalkyl can be monosubstituted or polysubstituted, and the substituents are respectively and independently selected from C1-C20, C1-C12, C1-C6, C1-C3 aliphatic group, halogen atoms such as F, Cl, Br, I and the like, nitro, amino, hydroxyl, alkoxy, cycloalkyl, C1-C20, C1-C12, C1-C6 aryl, C1-C20, C1-C12 and C1-C6 heteroaryl;
l is selected from hydrogen, C1-C20, C1-C12, C1-C6 and C1-C3 alkyl, in the group L, the alkyl can be monosubstituted or polysubstituted, and the substituent of the alkyl is selected from-NR 'R' substituted or unsubstituted C3-C9 cycloalkyl, wherein R 'and R' are respectively and independently selected from C1-C6 and C1-C3 alkyl;
m is selected from C1-C20, C1-C12, C1-C6 aryl or C1-C20, C1-C12, C1-C6 heteroaryl, in the group M, the aryl or heteroaryl can be monosubstituted or polysubstituted, and the substituents are selected from halogen atoms such as F, Cl, Br, I and the like, C1-C6 alkyl, C1-C6 alkoxy and-CF3、-OCF3And an alkylsulfonyl group. More specifically, there may be mentioned, but not limited to, the group structures corresponding to SAG (CAS number: 912545-86-9), LY2940680(CAS number: 1258861-20-9), GDC0449 (CAS number: 879085-55-9), LDE225(CAS number: 956697-53-3), SANT1(CAS number: 304909-07-7), SANT2(CAS number: 329196-48-7), and the like. In other embodiments of the present invention, B may be selected from the group shown below:
Figure BDA0001798453550000141
in the present invention, the aliphatic group generally refers to a chain hydrocarbon compound, and may be, for example, an alkyl group, an alkenyl group and an alkynyl group. The aliphatic group may be, but is not limited to, methyl, ethyl, ethenyl, ethynyl, propyl, propenyl, propynyl, butyl, butenyl, butynyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, and the like. The aliphatic group may contain a heteroatom, for example, the heteroatom may be N, S, P, O or the like.
In the present invention, the cycloalkyl group is understood to mean saturated and unsaturated (but not aromatic) cyclic hydrocarbons including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. For cycloalkyl, also included are saturated cycloalkyl groups, wherein optionally at least one carbon atom may be replaced by a heteroatom, a preferred heteroatom may be S, N, P or O, and the like. The monounsaturated or polyunsaturated (preferably monounsaturated) cycloalkyl group having no heteroatom in the ring also belongs to the cycloalkyl group as long as it is not an aromatic system.
In the present invention, the alkoxy group includes, but is not limited to, methoxy, ethoxy, propoxy, and the like. The alkoxy group may be mono-substituted or poly-substituted, the substituent of the alkoxy group includes but is not limited to halogen atoms such as F, Cl, Br, etc., and the substituted alkoxy group may include but is not limited to fluoropropoxy, trifluoroethoxy, etc.
In the present disclosure, the aryl group generally refers to a closed ring system having at least one aromatic ring, generally excluding heteroatoms (e.g., N, O, etc. the aryl group includes, but is not limited to, phenyl, naphthyl, fluoranthenyl, fluorenyl, tetrahydronaphthyl, indanyl, anthracenyl, phenanthrenyl, dihydrophenanthrenyl, and the like.
In the present invention heteroaryl is understood to mean a heterocyclic ring system having at least one aromatic ring and optionally containing one or more heteroatoms selected from N, O, S and the like, said heteroaromatic ring groups including but not limited to furyl, thienyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, benzofuryl, benzothienyl, indolyl, isoindolyl, benzimidazolyl, indazolyl, benzothiazolyl, benzoxazolyl, quinolyl, isoquinolyl, quinoxalinyl, phthalazinyl, quinazolinyl, cinnolinyl, purinyl, carbazolyl, dibenzofuryl, acridinyl, phenazinyl, phenoxazine, phenothiazine, phenoxathiin and the like.
In the smooth receptor ligands provided herein, the linker may be generally linear or inactive to the smooth receptor. The length of the linker, which generally may be a polyethylene glycol oligomer (PEG oligomer with triazole) having a triazole structure, has an effect on the activity of the ligand, and in some embodiments of the present invention, the structural formula of the linker is as follows:
Figure BDA0001798453550000151
wherein m and n are each independently selected from integers between 0 and 7, for example, m can be 0, 1,2, 3,4, 5, 6 or 7, and for example, n can be 0, 1,2, 3,4, 5, 6 or 7.
In some embodiments of the invention, the smoothing receptor ligand may be specifically selected from compounds of the structural formula:
Figure BDA0001798453550000152
Figure BDA0001798453550000161
Figure BDA0001798453550000171
Figure BDA0001798453550000181
Figure BDA0001798453550000191
Figure BDA0001798453550000201
Figure BDA0001798453550000211
Figure BDA0001798453550000221
in another aspect, the present invention provides the use of the smoothing receptor ligand or its isomer, prodrug, solvate, or pharmaceutically acceptable salt thereof in the preparation of smooth receptor (SMO receptor) agonists, inhibitors or antagonists. An agonist generally refers to a class of substances that promote a molecular activity, a response, or a pathway, and an inhibitor generally refers to a class of substances that decrease or block a molecular activity, a response, or a pathway. The antagonist generally refers to a substance that blocks an agonist-mediated effect of another substance upon binding to a receptor and does not itself cause the biological effect to which the substance corresponds. When the length of the linker is within a certain range, the linker-optimized bipitch molecule acts on the receptor in a mode of simultaneously binding two binding domains of the smooth receptor, and achieves higher activity through a synergistic effect, wherein the achieved activity type is generally related to the activity type of the ligand, for example, the achieved activity effect can be the effects of agonism, inhibition, antagonism and the like.
In another aspect, the present invention provides a pharmaceutical composition comprising a smooth receptor ligand as described above, or an isomer, prodrug, solvate, or pharmaceutically acceptable salt thereof. In the pharmaceutical composition, the smooth receptor ligand or an isomer, a prodrug, a solvate or a pharmaceutically acceptable salt thereof can be used as the only active ingredient, and can also be combined with at least one or more other active ingredients for combined administration.
The pharmaceutical composition provided by the invention can also comprise pharmaceutically acceptable auxiliary materials or additives, and the auxiliary materials or additives can be selected from carriers, excipients, supporting materials, auxiliaries, lubricants, fillers, solvents, diluents, coloring agents, flavoring agents and the like.
The pharmaceutical composition according to the invention may be adapted for administration in any form, be it oral or parenteral, in particular pulmonary, nasal, rectal and/or intravenous injection, etc., and may for example be suitable for topical or systemic application, in particular intradermal, subcutaneous, intramuscular, intra-articular, intraperitoneal, pulmonary, buccal, sublingual, buccal, nasal, transdermal, vaginal, oral or parenteral application, etc.
The novel double-headed small molecule ligand for the smooth receptor provided by the invention is combined with the crystal structure data of the smooth receptor, and a connector is introduced into a proper site of an ectodomain ligand and a transmembrane domain ligand to obtain a brand-new double-headed ligand small molecule, so that the interaction between the ligand and the receptor and the biological activity of the ligand are enhanced. The small molecular ligand can be used as a tool molecule for the function and structure research of a smooth receptor, and can also be used as a medicine development candidate of diseases related to the smooth receptor.
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments, and is not intended to limit the scope of the present invention; in the description and claims of the present application, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition to the specific methods, devices, and materials used in the examples, any methods, devices, and materials similar or equivalent to those described in the examples may be used in the practice of the invention in addition to the specific methods, devices, and materials used in the examples, in keeping with the knowledge of one skilled in the art and with the description of the invention.
Unless otherwise indicated, the experimental methods, detection methods, and preparation methods disclosed herein all employ techniques conventional in the art of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related arts. These techniques are well described in the literature, and may be found in particular in the study of the MOLECULAR CLONING, Sambrook et al: a LABORATORY MANUAL, Second edition, Cold Spring harbor LABORATORY Press, 1989 and Third edition, 2001; ausubel et al, Current PROTOCOLS Inmolecular BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; the series METHODS IN ENZYMOLOGY, Academic Press, San Diego; wolffe, CHROMATINSTRUCUTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; (iii) Methods Inenzymolygy, Vol.304, Chromatin (P.M. Wassarman and A.P.Wolffe, eds.), academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol.119, chromatography protocols (P.B.Becker, ed.) Humana Press, Totowa, 1999, etc.
Example 1
Ligand and synthesis thereof:
the double-head ligand of the smoothing receptor has the structural formulas (I) to (XXIX) respectively.
All the double-headed ligands are obtained by reacting an intermediate with an ethynyl group connected at one end and an intermediate with an azido group connected at one end under the catalysis of cuprous salt. The synthetic general formula of the double-head ligand is as follows:
Figure BDA0001798453550000241
: the bipitch ligand of the smooth receptor was synthesized by Click reaction. Reaction conditions are as follows: (a) CuSO4,sodiumascorbate, MeOH,r.t.,1h.
The intermediate structure and the number correspond to the following:
Figure BDA0001798453550000251
the fragment molecule synthesis method is as follows:
Figure BDA0001798453550000261
the reaction equation shown above is a synthetic route to TC577 and its homologues, and the reaction conditions are as follows:
(a)TBSCl,imidazole,DMAP,DMF/THF,r.t.,1h；
(b)6-bromo-1-hexene,Mg,THF,r.t.,3h；
(c)i.9-BBN,THF,r.t.,1h；ii.1M NaOH,H2O2,0℃ to r.t.,1h；
(d)3-bromo-1-propyne,NaH(60％),THF,50℃,2h；
(e)TBAF,THF,r.t.,1h；
(f)TsCl,Et3N,DMAP,DCM,r.t.,1h；
(g)ethylene glycol,NaH(60％),DMF,70℃,6h；
(h)1-propargyl oligo ethylene glycol,NaH(60％),THF,reflux,4-6h.
the preparation method comprises the following steps:
20.0g of pregnenolone, 18.0g of imidazole and 769mg of 4-Dimethylaminopyridine (DMAP) were dissolved in a mixed solvent of 30mL of N, N-Dimethylformamide (DMF) and 65mL of Tetrahydrofuran (THF), 18.0g of t-butyldimethylchlorosilane (TBSCl) was added thereto, and the mixture was stirred at room temperature for 1 hour. After the reaction is finished, 20mL of saturated ammonium chloride solution is added for quenching, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride water solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was subjected to thermal recrystallization in a mixed solvent of 100mL of n-hexane and 10mL of methylene chloride to obtain a mostly pure colorless crystalline intermediate 1. The mother liquor is separated by column chromatography (200-mesh silica gel of 300 meshes, eluent is normal hexane: ethyl acetate: 10:1) to obtain the pure intermediate 1.
28.8g of magnesium turnings were added to a dry, nitrogen-filled reaction flask. 10.0g of 6-bromo-1-hexene was dissolved in 60mL of anhydrous THF, about 1/10 of this solution was added to the magnesium turnings, 1 drop of 1, 2-dibromoethane was added and appropriate heating initiated the formation of the Grignard reagent. After the initiation is successful, the residual bromide solution is dripped into the magnesium chips, and the dripping speed is controlled to keep the reaction liquid slightly boiling. After the addition, the heating and refluxing were continued for 2 hours. The reaction solution is cooled, and the concentration of the Grignard reagent is calibrated by using elemental iodine. Typically, the Grignard reagent is synthesized in this method at a concentration of about 0.5 to about 0.7M.
In a dry, nitrogen-filled reaction flask, 5.0g of intermediate 1 was dissolved in 35mL of anhydrous THF, and 65mL of a 0.54M THF solution of 1- (5-hexenyl) magnesium bromide was added dropwise to the solution and stirred at room temperature for 3 hours. And after the reaction is finished, adding 50mL of saturated ammonium chloride solution to quench the reaction, separating an organic phase, extracting the water phase for three times by using dichloromethane, merging the organic phase, washing the organic phase by using saturated ammonium chloride aqueous solution and saturated common salt water in sequence, drying the organic phase by using anhydrous sodium sulfate, filtering the mixture to remove the sodium sulfate, and concentrating the filtrate to obtain a crude product. The crude product is separated by column chromatography (200-mesh silica gel 300-mesh, eluent n-hexane: ethyl acetate: 3:1) to obtain the pure intermediate 2.
2.0g of intermediate 2 were dissolved in 40mL of anhydrous THF in a dry, nitrogen-filled reaction flask, and 0.5M 9-borabicyclo [3.3.1 ] was added dropwise to this solution]40mL of nonane (9-BBN) in THF was stirred at room temperature for 1 hour. The reaction was then cooled to 0 ℃ and 20mL of 1M sodium hydroxide solution and 20mL of 30% hydrogen peroxide were slowly added dropwise with continued stirring at 0 ℃ for 1 hour. After the reaction is finished, 20mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate 1:1) to yield pure intermediate 3.1H NMR(500MHz,CDCl3),(ppm)0.06(s,6H,CH3), 0.86(s,3H,CH3),0.89(s,9H,CH3),0.90-0.98(m,1H,CH2),1.00(s,3H,CH3),1.01-1.25(m,4H, CH2andCH),1.26(s,3H,CH3),1.29-1.76(m,21H,CH2and CH),1.78-1.82(m,1H,CH2), 1.94-2.00(m,1H,CH2),2.05-2.10(m,1H,CH2),2.14-2.19(m,1H,CH2),2.24-2.30(m,1H,CH2), 3.46-3.50(m,1H,CH),3.63-3.65(t,J＝8.5Hz,2H,CH2),4.21(d,J＝2.0Hz,2H,CH2),5.31-5.32(m,1H,CH)；13C NMR(125MHz,CDCl3)δ(ppm)-4.6,13.6,18.3,19.4,20.9,22.3,23.8,24.2,25.7,25.9,26.4,30.0,31.3,31.8,32.0,32.7,36.6,37.3,40.1,42.6,42.8,43.8,50.1,56.9,57.6,63.0, 72.6,75.2,121.0,141.6.
To a solution of 106mg of intermediate 3 in 2mL of THF was added 16mg of NaH (60%), followed by stirring at room temperature for 15 minutes, followed by addition of 24mg of 3-bromopropyne, and heating to 50 ℃ for reaction for 2 hours. After the reaction is finished, 5mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was separated by column chromatography (200-300 mesh silica gel, eluent n-hexane: ethyl acetate: 3:1) to yield pure intermediate 4.1H NMR(500MHz,CDCl3),(ppm)0.06(s,6H,CH3),0.86(s,3H,CH3),0.89(s,9H,CH3), 0.91-0.98(m,1H,CH2),1.00(s,3H,CH3),1.01-1.22(m,4H,CH2and CH),1.26(s,3H,CH3), 1.29-1.76(m,21H,CH2and CH),1.78-1.82(m,1H,CH2),1.94-1.99(m,1H,CH2),2.06-2.10(m, 1H,CH2),2.15-2.19(m,1H,CH2),2.24-2.29(m,1H,CH2),2.42(t,J＝2.0Hz,1H,CH),3.46-3.52 (m,3H,CH2and CH),4.13(d,J＝2.5Hz,2H,CH2),5.31-5.32(m,1H,CH)；13C NMR(125MHz, CDCl3),-4.6,13.6,18.2,19.4,20.8,22.3,23.7,24.2,25.9,26.0,26.4,29.4,30.0,31.3,31.8,32.0,36.5,37.3,40.1,42.6,42.7,43.9,50.0,56.9,57.5,58.0,70.2,72.6,74.0,75.1,80.0,121.0, 141.5.
1mL T at 57mg intermediate 4To the HF solution, 0.5 mL of a THF solution of 1M tetrabutylammonium fluoride (TBAF) was added, and the mixture was stirred at room temperature for 1 hour. After the reaction is finished, the intermediate TC577 is obtained by concentration and column chromatography (200-mesh silica gel with 300 meshes, and an eluant of n-hexane and ethyl acetate which are 1: 1).1H NMR(500MHz,CDCl3),(ppm)0.86(s,3H, CH3),0.88-0.99(m,1H,CH2),1.01(s,3H,CH3),1.02-1.25(m,4H,CH2and CH),1.26(s,3H, CH3),1.27-1.78(m,20H,CH2and CH),1.82-1.86(m,2H,CH2),1.95-2.00(m,1H,CH2),2.07-2.11 (m,1H,CH2),2.20-2.32(m,2H,CH2),2.43(t,J＝2.0Hz,1H,CH),3.49-3.54(m,3H,CH2and CH),4.13(d,J＝2.5Hz,2H,CH2),5.35-5.36(m,1H,CH)；13C NMR(125MHz,CDCl3), 13.6,19.4,20.9,22.3,23.7,24.2,26.0,26.4,29.4,30.0,31.2,31.6,31.7,36.4,37.2,40.1,42.2,42.6,43.9,49.9,56.8,57.5,58.0,70.2,71.6,74.0,75.1,80.0,121.5,140.7.
5.32g of intermediate 3, 2.02g of triethylamine and 122mg of DMAP were dissolved in 50mL of Dichloromethane (DCM), and 2.85g of p-toluenesulfonyl chloride (TsCl) was added and stirred at room temperature for 1 hour. After the reaction, 40mL of saturated sodium bicarbonate solution is added to quench the reaction, an organic phase is separated, a water phase is extracted three times by dichloromethane, the organic phase is merged, the saturated sodium bicarbonate solution and the saturated sodium chloride solution are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 7:1) to yield pure intermediate 5.1H NMR(500MHz,CDCl3),(ppm)0.08(s,6H,CH3),0.87(s,3H,CH3),0.90(s,9H,CH3), 0.90-0.98(m,1H,CH2),0.99(s,3H,CH3),1.01-1.25(m,4H,CH2and CH),1.24(s,3H,CH3), 1.29-1.76(m,21H,CH2and CH),1.78-1.84(m,1H,CH2),1.93-1.98(m,1H,CH2),2.05-2.08(m, 1H,CH2),2.14-2.17(m,1H,CH2),2.22-2.27(m,1H,CH2),2.43(s,3H,CH3),3.43-3.53(m,1H, CH),4.00(t,J＝6.5Hz,2H,CH2),5.29-5.32(m,1H,CH),7.33(d,J＝8.0Hz,2H,CH),7.77(d,J ＝8.0Hz,2H,CH)；13C NMR(125MHz,CDCl3)δ(ppm)-3.6,13.6,18.2,19.4,20.9,21.6,22.3,23.7,24.0,25.3,25.6,25.9,26.3,28.8,29.5,31.3,31.6,31.8,32.0,32.7,36.5,37.2,40.1,42.2,42.6, 43.7,50.0,56.8,57.6,70.5,71.7,72.5,75.1,120.1,121.5,127.8,129.8,133.2,140.7,141.5,144.6.
To a mixed solution of 542mg of ethylene glycol and 5mL of DMF was added 146mg of NaH (60%), followed by stirring at room temperature for 15 minutes, followed by addition of 501mg of intermediate 5, and heating to 70 ℃ for reaction for 4 to 6 hours. After the reaction, 20mL of saturated ammonium chloride solution was added to quench the reaction, the reaction was extracted three times with dichloromethane, the organic phase was washed successively with saturated aqueous sodium bicarbonate solution and saturated brine, and then dried over anhydrous sodium sulfate, filtered to remove sodium sulfate, and concentrated to give a crude product. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 2:1) to yield pure intermediate 6.
To a solution of 117mg of intermediate 6 in 2mL of THF was added 16mg of NaH (60%), followed by stirring at room temperature for 15 minutes, followed by addition of 24mg of 3-bromopropyne, and heating to 50 ℃ for reaction for 2 hours. After the reaction is finished, 5mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent n-hexane: ethyl acetate: 3:1) to yield pure intermediate 7.1H NMR(500MHz,CDCl3),(ppm)0.06(s,6H,CH3),0.86(s,3H,CH3),0.89(s,9H,CH3), 0.90-0.98(m,1H,CH2),1.00(s,3H,CH3),1.01-1.25(m,4H,CH2and CH),1.26(s,3H,CH3), 1.29-1.76(m,21H,CH2and CH),1.78-1.82(m,1H,CH2),1.94-2.00(m,1H,CH2),2.05-2.10(m, 1H,CH2),2.15-2.19(m,1H,CH2),2.24-2.30(m,1H,CH2),2.44(t,J＝2.5Hz,1H,CH),3.44-3.51 (m,3H,CH2and CH),3.60-3.62(m,2H,CH2),3.69-3.71(m,2H,CH2),4.21(d,J＝2.0Hz,2H, CH2),5.31-5.32(m,1H,CH)；13C NMR(125MHz,CDCl3),-4.6,13.6,18.2,19.4,20.8,22.3, 23.7,24.2,25.9,26.0,26.4,29.5,30.0,31.2,31.7,32.0,36.5,37.3,40.0,42.6,42.7,43.9,50.0,56.8, 57.5,58.4,69.1,69.8,71.5,72.5,74.5,75.1,79.6,121.0,141.5.HRMScalcd for C38H66O4Si [M+Na]+:637.4623；found:637.4635.
To a solution of 61mg of intermediate 7 in 1mL of THF was added 0.5 mL of a 1M THF solution of tetrabutylammonium fluoride (TBAF), and the mixture was stirred at room temperature for 1 hour. After the reaction is finished, the intermediate TC573 is obtained by concentration and column chromatography (200-300 mesh silica gel, eluent is n-hexane: ethyl acetate ═ 1: 1).1H NMR(500MHz,CDCl3),(ppm)0.86(s,3H, CH3),0.88-0.99(m,1H,CH2),1.01(s,3H,CH3),1.02-1.25(m,4H,CH2and CH),1.26(s,3H, CH3),1.27-1.76(m,20H,CH2and CH),1.81-1.86(m,2H,CH2),1.95-1.99(m,1H,CH2),2.06-2.10 (m,1H,CH2),2.21-2.31(m,2H,CH2),2.44(t,J＝2.5Hz,1H,CH),3.44-3.54(m,3H,CH2and CH),3.60-3.62(m,2H,CH2),3.69-3.71(m,2H,CH2),4.21(d,J＝2.5Hz,2H,CH2),5.34-5.35(m,1H,CH)；13C NMR(125MHz,CDCl3),13.6,19.3,20.8,22.2,23.7,24.2,26.0,26.3,29.5,30.0,31.2,31.5,31.7,36.4,37.1,40.0,42.2,42.5,43.8,49.9,56.8,57.4,58.3,69.0,69.8,71.4,71.6, 74.5,75.2,79.6,121.5,140.7；HRMS calcd for C32H52O4[M+Na]+:523.3758；found:523.3757。
General procedure for the synthesis of TC574 and homologs (taking the synthesis of TC574 as an example):
to a solution of 58mg of 1-propargyldiglycol in 2mL of THF was added 24mg of NaH (60%), followed by stirring at room temperature for 15 minutes, followed by addition of intermediate 5 and heating under reflux for 6 hours. After the reaction is finished, 5mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product is subjected to column chromatography (200-mesh silica gel and 300-mesh eluent)Is n-hexane: ethyl acetate 5:1) isolated to give pure intermediate 8.1H NMR(500 MHz,CDCl3),(ppm)0.06(s,6H,CH3),0.86(s,3H,CH3),0.89(s,9H,CH3),0.90-0.98(m,1H, CH2),1.00(s,3H,CH3),1.01-1.25(m,4H,CH2and CH),1.26(s,3H,CH3),1.29-1.76(m,21H,CH2and CH),1.78-1.82(m,1H,CH2),1.95-1.99(m,1H,CH2),2.06-2.10(m,1H,CH2),2.15-2.19 (m,1H,CH2),2.24-2.30(m,1H,CH2),2.44(t,J＝2.5Hz,1H,CH),3.43-3.50(m,3H,CH2and CH),3.58-3.73(m,8H,CH2),4.21(d,J＝2.5Hz,2H,CH2),5.31-5.32(m,1H,CH)；13CNMR(125 MHz,CDCl3),-4.6,13.6,18.2,19.4,20.8,22.3,23.7,24.2,25.9,26.0,26.4,29.5,30.0,31.2, 31.7,32.0,36.5,37.3,40.0,42.6,42.7,43.9,50.0,56.8,57.5,58.4,69.0,70.0,70.4,70.6,71.4,72.5, 74.5,75.1,79.6,121.0,141.5；HRMS calcd forC40H70O5Si[M+Na]+:681.4885；found:681.4898.
Intermediate 9.1H NMR(500MHz,CDCl3),(ppm)0.06(s,6H,CH3),0.85(s,3H,CH3),0.89(s,9H,CH3),0.90-0.98(m,1H,CH2),1.00(s,3H,CH3),1.01-1.23(m,4H,CH2and CH),1.26(s, 3H,CH3),1.29-1.76(m,21H,CH2and CH),1.78-1.82(m,1H,CH2),1.94-1.99(m,1H,CH2), 2.06-2.10(m,1H,CH2),2.14-2.18(m,1H,CH2),2.24-2.29(m,1H,CH2),2.45(t,J＝2.5Hz,1H, CH),3.43-3.50(m,3H,CH2and CH),3.57-3.72(m,12H,CH2),4.20(d,J＝2.5Hz,2H,CH2), 5.31-5.32(m,1H,CH)；13C NMR(125MHz,CDCl3),-4.7,13.5,18.1,19.3,20.8,22.2,23.7, 24.1,25.8,25.9,26.3,29.4,30.0,31.2,31.6,31.9,36.4,37.2,40.0,42.5,42.6,43.8,49.9,56.8,57.4, 58.2,68.9,69.9,70.2,70.41,70.46,71.3,72.4,74.5,75.0,79.5,120.9,141.3；HRMS calcd for C42H74O6Si[M+Na]+:725.5147；found:725.5145.
An intermediate 10.1H NMR(500MHz,CDCl3),(ppm)0.06(s,6H,CH3),0.86(s,3H,CH3),0.89(s,9H,CH3),0.90-0.98(m,1H,CH2),1.00(s,3H,CH3),1.01-1.22(m,4H,CH2and CH),1.26(s, 3H,CH3),1.28-1.76(m,21H,CH2and CH),1.78-1.82(m,1H,CH2),1.94-1.99(m,1H,CH2), 2.06-2.10(m,1H,CH2),2.14-2.19(m,1H,CH2),2.24-2.30(m,1H,CH2),2.44(t,J＝2.5Hz,1H, CH),3.43-3.51(m,3H,CH2and CH),3.57-3.73(m,16H,CH2),4.20(d,J＝2.5Hz,2H,CH2), 5.31-5.32(m,1H,CH)；13C NMR(125MHz,CDCl3),-4.6,13.5,18.2,19.4,20.8,22.2,23.7, 24.2,25.9,26.0,26.4,29.5,30.0,31.2,31.7,32.0,36.5,37.3,40.0,42.5,42.7,43.9,50.0,56.8,57.4, 58.3,69.0,70.0,70.3,70.47,70.49,70.51,70.52,70.53,71.4,72.5,74.5,75.1,79.5,120.9,141.3； HRMS calcd for C44H78O7Si[M+Na]+:769.5409；found:769.5413.
Intermediate 11.1H NMR(500MHz,CDCl3),(ppm)0.06(s,6H,CH3),0.85(s,3H,CH3),0.89(s,9H,CH3),0.90-0.98(m,1H,CH2),1.00(s,3H,CH3),1.01-1.23(m,4H,CH2and CH),1.26(s, 3H,CH3),1.29-1.76(m,21H,CH2and CH),1.78-1.82(m,1H,CH2),1.94-1.99(m,1H,CH2), 2.06-2.10(m,1H,CH2),2.14-2.18(m,1H,CH2),2.24-2.29(m,1H,CH2),2.45(t,J＝2.5Hz,1H, CH),3.43-3.50(m,3H,CH2and CH),3.57-3.72(m,20H,CH2),4.20(d,J＝2.5Hz,2H,CH2), 5.31-5.32(m,1H,CH)；13C NMR(125MHz,CDCl3),-4.7,13.5,18.1,19.3,20.8,22.2,23.7, 24.1,25.8,25.9,26.3,29.4,30.0,31.2,31.6,31.9,36.4,37.2,40.0,42.5,42.6,43.8,49.9,56.8,57.4, 58.2,68.9,69.9,70.2,70.41,70.46,71.3,72.4,74.5,75.0,79.5,120.9,141.3；HRMS calcd for C46H82O8Si[M+Na]+:813.5671；found:813.5670.
Intermediate 12.1H NMR(500MHz,CDCl3),(ppm)0.06(s,6H,CH3),0.86(s,3H,CH3),0.89(s,9H,CH3),0.90-0.98(m,1H,CH2),1.00(s,3H,CH3),1.01-1.22(m,4H,CH2and CH),1.26(s, 3H,CH3),1.28-1.76(m,21H,CH2and CH),1.78-1.82(m,1H,CH2),1.94-1.99(m,1H,CH2), 2.06-2.10(m,1H,CH2),2.14-2.19(m,1H,CH2),2.24-2.30(m,1H,CH2),2.44(t,J＝2.5Hz,1H, CH),3.43-3.51(m,3H,CH2and CH),3.57-3.73(m,24H,CH2),4.20(d,J＝2.5Hz,2H,CH2), 5.31-5.32(m,1H,CH)；13C NMR(125MHz,CDCl3),(ppm)-4.6,13.5,18.2,19.4,20.8,22.2, 23.7,24.2,25.9,26.0,26.4,29.5,30.0,31.2,31.7,32.0,36.5,37.3,40.0,42.5,42.7,43.9,50.0,56.8, 57.4,58.3,69.0,70.0,70.3,70.47,70.49,70.51,70.52,70.53,71.4,72.5,74.5,75.1,79.5,120.9, 141.3；HRMS calcd for C48H86O9Si[M+Na]+:857.5933；found:857.5923.
To a solution of 65mg of intermediate 8 in 1mL of THF was added 0.5 mL of a 1M solution of tetrabutylammonium fluoride (TBAF) in THF, and the mixture was stirred at room temperature for 1 hour. After the reaction is finished, the intermediate TC574 is obtained by concentration and column chromatography (200-300 mesh silica gel, eluent is n-hexane: ethyl acetate ═ 1: 1).1H NMR(500MHz,CDCl3),(ppm)0.86(s,3H, CH3),0.88-0.99(m,1H,CH2),1.01(s,3H,CH3),1.02-1.24(m,4H,CH2and CH),1.26(s,3H, CH3),1.28-1.76(m,20H,CH2and CH),1.81-1.86(m,2H,CH2),1.95-2.01(m,1H,CH2),2.07-2.10 (m,1H,CH2),2.21-2.32(m,2H,CH2),2.44(t,J＝2.5Hz,1H,CH),3.44-3.54(m,3H,CH2and CH),3.58-3.60(m,2H,CH2),3.63-3.72(m,6H,CH2),4.21(d,J＝2.5Hz,2H,CH2),5.34-5.35(m,1H,CH)；13C NMR(125MHz,CDCl3),13.6,19.3,20.8,22.2,23.7,24.2,26.0,26.3,29.5,30.0,31.2,31.5,31.7,36.4,37.2,40.0,42.2,42.5,43.9,49.9,56.8,57.4,58.3,69.0,70.0,70.3,70.6, 71.4,71.6,74.5,75.1,79.6,121.5,140.7；HRMS calcd for C34H56O5[M+Na]+:567.4020；found: 567.4017。
TC575。1H NMR(500MHz,CDCl3),(ppm)0.86(s,3H,CH3),0.88-0.99(m,1H,CH2),1.01(s,3H,CH3),1.02-1.23(m,4H,CH2and CH),1.26(s,3H,CH3),1.28-1.76(m,20H,CH2andCH),1.81-1.86(m,2H,CH2),1.95-1.99(m,1H,CH2),2.06-2.10(m,1H,CH2),2.20-2.30(m,2H, CH2),2.45(t,J＝2.5Hz,1H,CH),3.43-3.53(m,3H,CH2and CH),3.57-3.59(m,2H,CH2),3.63-3.72(m,10H,CH2),4.20(d,J＝2.5Hz,2H,CH2),5.34-5.35(m,1H,CH)；13C NMR(125MHz,CDCl3),13.5,19.3,20.8,22.2,23.6,24.1,25.9,26.3,29.4,30.0,31.1,31.4,31.6,36.3, 37.1,39.9,42.1,42.4,43.8,49.8,56.7,57.4,58.2,68.9,69.9,70.2,70.40,70.44,71.3,71.4,74.5, 75.1,79.5,121.3,140.7；HRMS calcd for C36H60O6[M+Na]+:611.4282；found:611.4289。
TC568。1H NMR(500MHz,CDCl3),(ppm)0.86(s,3H,CH3),0.88-0.99(m,1H,CH2),1.01(s,3H,CH3),1.02-1.23(m,4H,CH2and CH),1.26(s,3H,CH3),1.28-1.76(m,20H,CH2andCH),1.81-1.86(m,2H,CH2),1.95-2.00(m,1H,CH2),2.06-2.10(m,1H,CH2),2.20-2.31(m,2H, CH2),2.45(t,J＝2.5Hz,1H,CH),3.43-3.55(m,3H,CH2and CH),3.57-3.60(m,2H,CH2),3.63-3.72(m,14H,CH2),4.21(d,J＝2.5Hz,2H,CH2),5.34-5.35(m,1H,CH)；13C NMR(125MHz,CDCl3),13.5,19.3,20.8,22.2,23.7,24.1,26.0,26.3,29.5,30.0,31.2,31.5,31.7,36.4, 37.1,40.0,42.1,42.5,43.8,49.9,56.8,57.4,58.3,69.0,69.9,70.3,70.43,70.44,70.47,71.4,71.6, 74.5,75.1,79.5,121.5,140.7；HRMS calcd for C38H64O7[M+Na]+:655.4544；found:655.4550。
TC569。1H NMR(500MHz,CDCl3),(ppm)0.86(s,3H,CH3),0.88-0.99(m,1H,CH2),1.01(s,3H,CH3),1.02-1.23(m,4H,CH2and CH),1.26(s,3H,CH3),1.28-1.76(m,20H,CH2andCH),1.82-1.86(m,2H,CH2),1.95-2.00(m,1H,CH2),2.06-2.10(m,1H,CH2),2.21-2.32(m,2H, CH2),2.45(t,J＝2.5Hz,1H,CH),3.43-3.54(m,3H,CH2and CH),3.57-3.74(m,20H,CH2),4.21 (d,J＝2.5Hz,2H,CH2),5.35-5.36(m,1H,CH)；13C NMR(125MHz,CDCl3),13.5,19.3, 20.8,22.2,23.7,24.2,26.0,26.3,29.5,30.0,31.2,31.5,31.7,36.4,37.1,40.0,42.1,42.5,43.8,49.9, 56.8,57.4,58.3,69.0,69.9,70.3,70.46,70.48,70.51,71.4,71.6,74.5,75.2,79.6,121.5,140.7； HRMS calcd for C40H68O8[M+Na]+:699.4806；found:699.4800。
TC570。1H NMR(500MHz,CDCl3),(ppm)0.86(s,3H,CH3),0.88-0.99(m,1H,CH2),1.01(s,3H,CH3),1.02-1.23(m,4H,CH2and CH),1.26(s,3H,CH3),1.28-1.76(m,20H,CH2andCH),1.82-1.86(m,2H,CH2),1.95-2.02(m,1H,CH2),2.07-2.10(m,1H,CH2),2.21-2.32(m,2H, CH2),2.45(t,J＝2.5Hz,1H,CH),3.43-3.55(m,3H,CH2and CH),3.57-3.59(m,2H,CH2),3.63-3.72(m,22H,CH2),4.21(d,J＝2.5Hz,2H,CH2),5.35-5.36(m,1H,CH)；13C NMR(125MHz,CDCl3),13.5,19.3,20.8,22.3,23.7,24.2,26.0,26.4,29.5,30.0,31.2,31.5,31.7,36.4, 37.2,40.0,42.2,42.6,43.9,49.9,56.8,57.4,58.3,69.0,69.9,70.3,70.49,70.50,70.53,71.4,71.6, 74.5,75.1,79.6,121.5,140.7；HRMS calcd for C42H72O9[M+Na]+:744.5141；found:743.5070。
Figure BDA0001798453550000331
The reaction equation shown above is a synthetic route of TC819, and the reaction conditions are specifically as follows:
(a)5-amino-1-pentanol,NaBH(OAc)3,AcOH,DCE,r.t.,7days；
(b)Boc2O,DCM,r.t.,2h；
(c)TsCl,Et3N,DMAP,DCM,r.t.,1h；
(d)ethylene glycol,NaH(60％),DMF,70℃,6h；
(e)3-bromo-1-propyne,NaH(60％),THF,50℃,2h；
(f)2N HCl in dioxane,r.t.,2h.
8.6g of intermediate 1, 8.2g of 5-amino-1-pentanol, 4.8g of glacial acetic acid are dissolved in 100mL1, 2-Dichloroethane (DCE), and 17.0g of sodium triacetoxyborohydride (NaBH (OAc))3) And stirring at room temperature. After the reaction is finished, 100mL of saturated sodium bicarbonate solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by dichloromethane, the organic phase is merged, the saturated sodium bicarbonate solution and the saturated sodium chloride solution are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent dichloromethane: methanol: 10:1) to yield pure intermediate 13.1H NMR(500MHz,CDCl3),(ppm)0.06(s,6H,CH3),0.70(s,3H, CH3),0.72(s,3H,CH3),0.89(s,9H,CH3),0.90-0.98(m,1H,CH2),0.99(s,3H,CH3),1.00(s,3H, CH3),1.01-1.25(m,4H,CH2and CH),1.05(d,J＝6.5Hz,3H,CH3),1.22(d,J＝6.5Hz,3H,CH3),1.28-1.73(m,21H,CH2and CH),1.78-1.82(m,1H,CH2),1.92-1.97(m,2H,CH2),2.15-2.18(m, 1H,CH2),2.24-2.29(m,1H,CH2),2.51-2.67(m,1H,CH2),2.72-2.84(m,1H,CH2),3.45-3.51(m, 1H,CH),3.62(t,J＝8.5Hz,2H,CH2),5.30-5.31(m,1H,CH)；13C NMR(125MHz,CDCl3)δ (ppm)-4.6,12.0,12.4,17.6,18.2,19.4,20.8,21.0,23.1,23.4,24.2,25.9,26.1,26.7,27.4,28.8, 31.7,31.8,32.0,32.2,37.3,39.1,39.7,42.7,40.9,50.0,54.9,55.3,56.2,56.4,61.7,62.0,72.6, 120.9,141.6；HRMS calcd for C32H59NO2Si[M+H]+:518.4388；found:518.4390.
To a solution of 2.07g of intermediate 13 in 20mL of DCM was added 959mg of di-tert-butyl dicarbonate (Boc)2O), stirred at room temperature for 2 hours. After the reaction is finished, concentrating, and performing column chromatography (200-mesh 300-mesh silica gel, wherein the eluent is n-hexane: ethyl acetate 5:1) isolated to yield pure intermediate 14.1H NMR(500MHz,CDCl3),(ppm)0.05(s,6H,CH3),0.72 and 0.76(s,3H,CH3),0.89(s,9H,CH3),0.90-0.95(m,1H,CH2),0.99 and 1.00(s,3H,CH3),1.01-1.24 (m,4H,CH2and CH),1.33-1.34(m,3H,CH),1.45(s,3H CH3),1.50-1.98(m,21H,CH2andCH), 2.15-2.18(m,1H,CH2),2.24-2.29(m,1H,CH2),3.45-3.47(m,1H,CH),3.65(t,J＝8.5Hz,2H, CH2),5.30-5.31(m,1H,CH)；13C NMR(125MHz,CDCl3)δ(ppm)-4.6,12.3,18.2,19.4,20.9, 21.0,23.7,23.9,24.2,25.9,28.5,28.6,29.2,30.3,31.8,32.0,32.4,36.5,37.3,39.1,41.4,41.9,42.0, 42.7,50.0,51.8,54.8,55.3,57.0,62.6,62.7,72.5,121.0,141.5,156.0；HRMS calcd for C37H67NO4Si[M+Na]+:640.4732；found:640.4727.
1.23g of intermediate 14, 404mg of triethylamine and 24mg of DMAP were dissolved in 10mL of DCM, 570mg of TsCl was added, and the mixture was stirred at room temperature for 1 hour. After the reaction, 20mL of saturated sodium bicarbonate solution is added to quench the reaction, an organic phase is separated, an aqueous phase is extracted three times by dichloromethane, the organic phase is merged, the saturated sodium bicarbonate solution and the saturated sodium chloride solution are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 7:1) to yield pure intermediate 15.1H NMR(500MHz,CDCl3), (ppm)0.05(s,6H,CH3),0.71 and 0.75(s,3H,CH3),0.89(s,9H,CH3),0.99 and 1.00(s,3H, CH3),1.08-1.29(m,10H,CH2and CH),1.43(s,3H CH3),1.50-1.98(m,17H,CH2and CH), 2.15-2.29(m,2H,CH2),2.45(s,3H,CH3),2.71-2.88(m,1H,CH),2.97-3.11(m,1H,CH), 3.46-3.50(m,1H,CH),4.01-4.11(m,2H,CH2),4.25-4.31(m,1H,CH),5.30-5.31(m,1H,CH), 7.34(d,J＝8.0Hz,2H,CH),7.79(d,J＝8.0Hz,2H,CH)；13C NMR(125MHz,CDCl3)δ(ppm) -4.6,12.3,18.2,19.4,20.9,21.6,23.3,23.9,25.9,28.5,28.6,29.2,31.8,32.0,36.5,37.3,39.2,41.4, 41.9,42.7,50.1,51.8,54.8,70.4,72.5,121.0,127.8,129.8,133.1,141.5,144.7；HRMS calcd for C44H73NO6SSi[M+Na]+:794.4820；found:794.4820.
To a mixed solution of 996mg of ethylene glycol and 10mL of DMF was added 300mg of NaH (60%), followed by stirring at room temperature for 15 minutes, then 1.16g of intermediate 15 was added, and the mixture was heated to 70 ℃ to react for 6 hours. After the reaction, 20mL of saturated ammonium chloride solution is added to quench the reaction, the reaction solution is extracted with dichloromethane for three times, the reaction solution is washed with saturated ammonium chloride aqueous solution and saturated brine in sequence, and then dried with anhydrous sodium sulfate, filtered to remove sodium sulfate, and concentrated to obtain a crude product. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent n-hexane: ethyl acetate: 3:1) to yield pure intermediate 16.1H NMR(500MHz,CDCl3), (ppm)0.06(s,6H,CH3),0.72 and 0.76(s,3H,CH3),0.89(s,9H,CH3),0.99 and 1.00(s,3H, CH3),1.02-1.35(m,10H,CH2and CH),1.45(s,3H CH3),1.52-1.98(m,15H,CH2and CH), 2.15-2.27(m,2H,CH2),3.02-3.24(m,1H,CH),3.46-3.55(m,5H,CH2and CH),3.71-3.74(m,2H,CH2),5.30-5.31(m,1H,CH)；13C NMR(125MHz,CDCl3)δ(ppm)-4.6,12.1,12.2,18.1,19.30,19.34,19.8,20.2,20.9,23.8,24.0,25.8,28.46,28.51,28.6,29.1,29.3,30.2,31.70,31.77,31.9, 36.4,37.2,39.2,41.4,41.8,42.0,42.7,50.1,51.7,54.7,54.9,56.0,57.0,61.6,71.1,71.7,72.5,78.7, 78.9,120.1,141.4,155.1,155.9；HRMS calcd forC39H71NO5Si[M+Na]+:684.4994；found: 684.4991.
To 662mg of intermediate 16 in 10mL of THF was added 80mg of NaH (60%), followed by stirring at room temperature for 15 minutes, 357mg of 3-bromopropyne was added, and the mixture was heated to 50 ℃ for reaction for 2 hours. After the reaction is finished, 20mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. Performing column chromatography on the crude product (200-30)0 mesh silica gel, eluent n-hexane: ethyl acetate 7:1) isolated to yield pure intermediate 17. HRMScalcd for C42H73NO5Si[M+Na]+:722.5150；found:722.5146.
To a solution of 140mg of intermediate 17 in 2mL of dioxane was added 2mL of 4M HCl in dioxane, and the mixture was stirred at room temperature for 2 hours. After the reaction is finished, the intermediate TC819 is obtained by concentration and column chromatography (200-300 mesh silica gel, eluent is dichloromethane: methanol: 10: 1).1H NMR(600MHz,CDCl3),(ppm)0.75 and 0.76(s,3H, CH3),0.78-1.00(m,2H,CH),1.02 and 1.03(s,3H,CH3),1.06-1.31(m,7H,CH2),1.34 and 1.41(s, 3H,CH3),1.43-1.68(m,15H,CH2and CH),1.72-1.89(m,9H,CH2and CH),1.93-2.02(m,3H, CH2),2.20-2.30(m,2H,CH2),2.58(t,J＝2.4Hz,1H,CH),2.89-2.96(m,2H,CH2),3.21-3.24(m, 1H,CH),3.34-3.36(m,1H,CH2),3.45-3.52(m,4H,CH2),3.58-3.63(m,3H,CH2),3.70-3.73(m, 3H,CH2),4.21(d,J＝2.4Hz,2H,CH2),5.34-5.35(m,1H,CH)；13C NMR(150MHz,CDCl3), (ppm)11.4,11.9,14.8,15.6,18.85,18.87,20.3,20.4,23.0,23.5,23.6,23.8,25.26,25.29,25.9, 28.41,28.43,30.6,31.20,31.24,31.26,31.30,36.0,36.1,36.81,36.84,37.2,38.6,41.3,41.9,42.1, 42.2,43.0,49.4,49.6,51.0,52.0,53.5,55.4,55.9,56.6,57.9,60.8,68.6,69.4,70.4,70.70,70.72, 71.9,74.5,78.9,120.67,120.70,140.5；HRMS calcd for C31H51NO3[M+H]+:486.3942；found: 486.3932.
Figure BDA0001798453550000361
The reaction equation shown above is a synthetic route of TC818, and the reaction conditions are as follows:
(a)p-TsOH,MeOH,60℃,12h；
(b)TBSCl,imidazole,DMAP,DMF/THF,r.t.,1h；
(c)LiAlH4,THF,50℃,1h；
(d)TsCl,Et3N,DMAP,DCM,r.t.,1h；
(e)allylmagnesium bromide,Li2CuCl4,THF,-78℃ to r.t.,12h；
(f)i.9-BBN,THF,r.t.,1h；ii.1M NaOH,H2O2,r.t.,1h；
(g)ethylene glycol,NaH(60％),DMF,70℃,6h；
(h)3-bromo-1-propyne,NaH(60％),THF,50℃,2h；
(i)TBAF,THF,r.t.,1h.
to a solution of 2.0g of 3-hydroxy-5-cholenic acid in 30mL of methanol was added 95mg of p-toluenesulfonic acid (p-TsOH), and the mixture was heated to 60 ℃ and stirred for 2 hours. After the reaction, the reaction mixture was concentrated to remove the solvent, dissolved in 100mL of ethyl acetate, washed with saturated aqueous sodium bicarbonate and saturated brine in this order, dried over anhydrous sodium sulfate, filtered to remove sodium sulfate, and concentrated to give a crude product, which was dissolved in a mixed solvent of 3mL of DMF and 5mL of THF, to which 680mg of imidazole, 64mg of DMAP and 1.5g of TBSCl were added, followed by stirring at room temperature for 1 hour. After the reaction, 20mL of saturated sodium bicarbonate solution is added to quench the reaction, an organic phase is separated, an aqueous phase is extracted three times by dichloromethane, the organic phase is merged, the saturated sodium bicarbonate solution and the saturated sodium chloride solution are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent n-hexane: ethyl acetate: 20:1) to yield pure intermediate 18.1H NMR(500MHz, CDCl3),(ppm)0.06(s,6H,CH3),0.67(s,3H,CH3),0.89(s,9H,CH3),0.90(d,J＝6.5Hz,3H, CH3),0.93-0.97(m,1H,CH2),1.00(s,3H,CH3),1.01-1.60(m,H,CH2and CH),1.68-1.73(m,1H, CH),1.78-1.86(m,2H,CH2),1.93-2.06(m,4H,CH2),2.14-2.18(m,1H,CH2),2.24-2.30(m,1H, CH2),3.44-3.51(m,1H,CH),4.91-5.01(m,2H,CH2),5.30-5.32(m,1H,CH)；5.77-5.85(m,1H, CH),13C NMR(125MHz,CDCl3)δ(ppm)-4.6,11.8,18.2,18.7,19.4,21.1,24.3,25.6,25.9,28.2, 29.4,31.9,31.9,32.1,33.9,35.7,35.8,36.6,37.4,39.8,42.3,42.8,50.2,56.1,56.8,72.6,114.1,121.1,139.2,141.5.
To a solution of 2.66g of intermediate 18 in 30ml of THF under ice bath was slowly added 570mg of lithium aluminum hydride (LiAlH)4) The reaction was heated to 50 ℃ for 1 hour. After the reaction is finished, 30mL of saturated ammonium chloride solution is carefully added in an ice bath to quench the reaction, an organic phase is separated, an aqueous phase is extracted three times by dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt solution are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 10:1) to yield pure intermediate 19.
2.51g of intermediate 19, 1.01g of triethylamine and 61mg of DMAP were dissolved in 30mL of DCM, 1.9g of TsCl was added, and the mixture was stirred at room temperature for 1 hour. After the reaction is finished, 30mL of saturated sodium bicarbonate solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by dichloromethane, the organic phase is merged, the saturated sodium bicarbonate solution and the saturated sodium chloride solution are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent n-hexane: ethyl acetate: 10:1) to yield pure intermediate 20.1H NMR(500MHz,CDCl3), (ppm)0.06(s,6H,CH3),0.64(s,3H,CH3),0.87(d,J＝6.5Hz,3H,CH3),0.89(s,9H,CH3), 0.91-0.97(m,1H,CH),0.99(s,3H,CH3),1.00-1.57(m,16H,CH2and CH),1.66-1.82(m,4H, CH2),1.93-1.99(m,2H,CH2),2.14-2.18(m,1H,CH2),2.23-2.29(m,1H,CH2),2.45(s,3H,CH3), 3.44-3.50(m,1H,CH),3.96-4.04(m,2H,CH2),5.31-5.32(m,1H,CH),7.34(d,J＝8.0Hz,2H, CH),7.79(d,J＝8.0Hz,2H,CH)；13C NMR(125MHz,CDCl3),(ppm)-4.6,11.8,18.3,18.5, 19.4,21.0,21.6,24.2,25.6,26.0,28.1,31.4,32.0,32.1,35.2,36.5,37.4,39.8,42.3,42.8,50.2,55.8, 56.8,71.2,72.6,121.1,127.9,129.8,133.3,141.6,144.6.
2.63g of intermediate 20 are dissolved in 20mL of anhydrous THF in a dry, nitrogen-filled reaction flask, and 1mL of 0.1M lithium tetrachlorocuprate are added dropwise to this solution at-78 deg.CAnd 4.9mL of a 1.7M solution of allylmagnesium bromide in THF, then allowed to warm slowly to room temperature after the addition and continued stirring for 12 hours. And after the reaction is finished, adding 30mL of saturated ammonium chloride solution to quench the reaction, separating an organic phase, extracting the water phase for three times by using dichloromethane, merging the organic phase, washing the organic phase by using saturated ammonium chloride aqueous solution and saturated common salt water in sequence, drying the organic phase by using anhydrous sodium sulfate, filtering the mixture to remove the sodium sulfate, and concentrating the filtrate to obtain a crude product. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent n-hexane: ethyl acetate: 100:1) to yield pure intermediate 21.1HNMR(500MHz,CDCl3),(ppm)0.06(s,6H,CH3),0.67(s,3H,CH3),0.89(s,9H,CH3), 0.91(d,J＝6.5Hz,3H,CH3),0.99(s,3H,CH3),1.01-1.60(m,20H,CH2and CH),1.69-1.73(m, 1H,CH2),1.78-1.85(m,2H,CH2),1.93-2.06(m,4H,CH2),2.14-2.18(m,1H,CH2),2.24-2.29(m,1H,CH2),3.46-3.90(m,1H,CH),4.91-5.01(m,2H,CH2),5.30-5.32(m,1H,CH),5.77-5.85(m,1H,CH)；13C NMR(125MHz,CDCl3),(ppm)-4.6,11.8,18.2,18.7,19.4,21.1,24.3,25.6,25.9, 28.2,29.4,31.91,31.94,32.1,33.9,35.7,35.8,36.6,37.4,39.8,42.3,42.8,50.2,56.1,56.8,72.6, 114.1,121.1,139.2,141.5.
In a dry, nitrogen-filled reaction flask, 1.79g of intermediate 21 was dissolved in 25mL of anhydrous THF, and 36mL of a 0.5M solution of 9-BBN in THF was added dropwise to the solution and stirred at room temperature for 1 hour. The reaction was then cooled to 0 ℃ and 4mL of 1M sodium hydroxide solution and 4mL of 30% hydrogen peroxide were slowly added dropwise with continued stirring for 1 hour. After the reaction is finished, 60mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 10:1) to yield pure intermediate 22.1H NMR(500MHz,CDCl3),(ppm)0.06(s,6H,CH3),0.67(s,3H,CH3),0.89(s, 9H,CH3),0.91(d,J＝6.0Hz,3H,CH3),1.00(s,3H,CH3),1.03-1.58(m,26H,CH2and CH), 1.68-1.73(m,1H,CH2),1.78-1.84(m,2H,CH2),1.94-2.02(m,2H,CH2),2.14-2.18(m,1H,CH2), 2.23-2.29(m,1H,CH2),3.45-3.51(m,1H,CH),3.64(t,J＝3.5Hz,2H,CH2),5.30-5.32(m,1H, CH)；13C NMR(125MHz,CDCl3),(ppm)-4.6,11.8,18.3,18.7,19.4,21.1,24.3,25.8,25.94, 26.00,28.2,29.9,31.90,31.94,32.1,32.8,35.7,35.9,36.6,37.4,39.8,42.3,42.8,50.2,56.1,56.8, 63.1,72.6,121.1,141.6.
2.82g of intermediate 22, 1.01g of triethylamine and 61mg of DMAP were dissolved in 30mL of DCM, 1.9g of TsCl was added, and the mixture was stirred at room temperature for 1 hour. After the reaction is finished, 30mL of saturated sodium bicarbonate solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by dichloromethane, the organic phase is merged, the saturated sodium bicarbonate solution and the saturated sodium chloride solution are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 10:1) to yield pure intermediate 23.1H NMR(500MHz,CDCl3), (ppm)0.06(s,6H,CH3),0.66(s,3H,CH3),0.89(s,9H,CH3),0.90(d,J＝6.0Hz,3H,CH3), 0.92-0.97(m,2H,CH2),1.00(s,3H,CH3),1.04-1.84(m,28H,CH2and CH),1.94-2.01(m,2H, CH2),2.15-2.18(m,1H,CH2),2.24-2.29(m,1H,CH2),2.45(s,3H,CH3),3.45-3.51(m,1H,CH), 4.01(t,J＝6.5Hz,2H,CH2),5.31-5.32(m,1H,CH),7.34(d,J＝8.0Hz,2H,CH),7.79(d,J＝8.0 Hz,2H,CH)；13C NMR(125MHz,CDCl3),(ppm)-4.6,11.8,18.2,18.6,19.4,21.0,21.6,24.2, 25.3,25.7,25.9,28.2,28.8,29.4,31.8,31.9,32.0,35.6,35.7,36.5,37.3,39.7,42.2,42.8,50.1,56.0, 56.7,70.6,72.6,121.1,127.8,129.7,133.1,141.4,144.5.
To a mixed solution of 542mg of ethylene glycol and 5mL of DMF was added 146mg of NaH (60%), followed by stirring at room temperature for 15 minutes, and then 489mg of intermediate 23 was added, followed by heating to 70 ℃ for reaction for 6 hours. After the reaction is finished, 30mL of saturated ammonium chloride solution is added to quench the reaction, and the reaction product is separatedThe organic phase and the aqueous phase were extracted three times with dichloromethane, the organic phases were combined, washed successively with saturated aqueous ammonium chloride and saturated brine, then dried over anhydrous sodium sulfate, filtered to remove sodium sulfate, and concentrated to give a crude product. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 5:1) to yield pure intermediate 24.1HNMR(500MHz,CDCl3),(ppm)0.06(s,6H,CH3),0.67(s,3H,CH3),0.89(s,9H, CH3),0.91(d,J＝6.0Hz,3H,CH3),1.00(s,3H,CH3),1.02-1.61(m,25H,CH2and CH),1.70-1.73 (m,3H,CH2),1.78-1.86(m,2H,CH2),1.94-2.01(m,2H,CH2),2.11-2.18(m,2H,CH2),2.24-2.29 (m,1H,CH2),3.45-3.51(m,3H,CH),3.54(t,J＝4.5Hz,2H,CH2),3.73(br,2H,CH2),5.31-5.32(m,1H,CH)；13C NMR(125MHz,CDCl3),(ppm)-4.6,11.8,18.2,18.7,19.4,21.0,24.3,25.92,25.97,26.1,28.2,29.7,30.0,31.89,31.93,32.1,35.7,35.9,36.6,37.4,39.8,42.3,42.8,50.2,56.1, 56.8,61.8,71.4,71.7,72.6,121.1,141.5.
To a solution of 112mg of intermediate 24 in 2mL of THF was added 16mg of NaH (60%), followed by stirring at room temperature for 15 minutes, followed by addition of 24mg of 3-bromopropyne, and heating to 50 ℃ for reaction for 2 hours. After the reaction is finished, 10mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 20:1) to yield pure intermediate 25.1H NMR(500MHz,CDCl3),(ppm)0.06(s,6H,CH3),0.67(s,3H,CH3),0.89(s,9H,CH3), 0.90(d,J＝6.5Hz,3H,CH3),0.93-0.98(m,1H,CH2),1.00(s,3H,CH3),1.01-1.60(m,24H,CH2and CH),1.69-1.73(m,1H,CH2),1.78-1.86(m,2H,CH2),1.94-2.02(m,2H,CH2),2.14-2.18(m, 1H,CH2),2.24-2.29(m,1H,CH2),2.43(t,J＝2.5Hz,1H,CH),3.44-3.51(m,3H,CH2and CH),3.60-3.62(m,2H,CH2),3.68-3.71(m,2H,CH2),4.21(d,J＝2.5Hz,2H,CH2),5.31-5.32(m,1H, CH)；13C NMR(125MHz,CDCl3),-4.6,11.8,18.3,18.7,19.4,21.0,24.3,25.9,26.1,28.2, 29.6,30.0,31.87,31.92,32.06,35.7,35.9,36.6,37.4,39.8,42.3,42.8,50.2,56.0,56.8,58.4,69.1, 69.8,71.6,72.6,74.4,79.7,121.1,141.5.
To a solution of 120mg of intermediate 25 in 2mL of THF was added 0.6mL of a THF solution of 1M tetrabutylammonium fluoride (TBAF), and the mixture was stirred at room temperature for 1 hour. After the reaction is finished, the intermediate TC818 is obtained by concentration and column chromatography (200-300 mesh silica gel, eluent is n-hexane: ethyl acetate ═ 3: 1).1H NMR(500MHz,CDCl3),(ppm)0.67(s, 3H,CH3),0.91(d,J＝6.0Hz,3H,CH3),0.92-0.99(m,1H,CH2),1.00(s,3H,CH3),1.02-1.62(m, 24H,CH2and CH),1.78-1.86(m,5H,CH2),1.94-2.02(m,2H,CH2),2.20-2.31(m,2H,CH2),2.43(t,J＝2.5Hz,1H,CH),3.46(t,J＝2.0Hz,2H,CH2),3.48-3.55(m,1H,CH),3.60-3.62(m,2H,CH2),3.68-3.70(m,2H,CH2),4.21(d,J＝2.0Hz,2H,CH2),5.34-5.35(m,1H,CH)；13C NMR(125MHz,CDCl3),(ppm)11.8,18.7,19.4,21.0,24.2,25.9,26.1,28.2,29.6,29.9,31.6,31.8, 35.7,35.8,36.4,37.2,39.7,42.23,42.26,50.1,56.0,56.7,58.4,69.1,69.8,71.6,71.7,74.4,79.6, 121.6,140.7.
Figure BDA0001798453550000401
The reaction equation shown above is a synthetic route of TC667, and the reaction conditions are as follows:
(a)NaH(60％),THF,reflux,6h；
(b)HATU,DIPEA,DCM,r.t.,2h.
120mg of NaH (60%) was added to a solution of 144mg of 1-propargyldiglycol in 5mL of THF, and the mixture was stirred at room temperature for 15 minutes, followed by addition of 152mg of bromoacetic acid and heating under reflux for 6 hours. After the reaction is finished, 10mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, and water is addedThe phases were extracted three times with dichloromethane, the organic phase was combined, washed successively with saturated aqueous ammonium chloride and saturated brine, then dried over anhydrous sodium sulfate, filtered to remove sodium sulfate and concentrated to give the crude product. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent dichloromethane: methanol: 50:1) to yield pure intermediate 26.1H NMR(500MHz,CDCl3),δ(ppm)2.46(t,J＝2.0Hz,1H,CH),3.70–3.78(m,8H,CH2),4.19(s, 2H,CH2),4.21(d,J＝2.5Hz,CH2)；13C NMR(125MHz,CDCl3),δ(ppm)58.5,68.6,69.0,70.4,70.5,71.2,74.8,79.5,173.6；HRMS calcd for C9H14O5[M+Na]+:225.0733；found:225.0746.
73mg of intermediate 26 and 153mg of O- (7-Azotobenzotriazol) -N, N, N, N-tetramethyluronium Hexafluorophosphate (HATU) were dissolved in 3mL of DCM and stirred at room temperature for 0.5 hour. To this solution was added 123mg cyclopamine and 58mg Diisopropylethylamine (DIPEA) in 2mL DCM and stirred at room temperature for 2 hours. After the reaction is finished, 10mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent dichloromethane: methanol: 20:1) to yield the pure intermediate TC 667.
Figure BDA0001798453550000411
The reaction equation shown above is a synthetic route of TC558, and the reaction conditions are as follows:
(a)p-TsOH,MeOH,60℃,12h；
(b)TBSCl,imidazole,DMAP,DMF/THF,r.t.,1h；
(c)LiAlH4,THF,50℃,1h；
(d)TsCl,Et3N,DMAP,DCM,r.t.,1h；
(e)1-propargyl diethylene glycol,NaH(60％),DMF,70℃,4-6h；
(f)TBAF,THF,r.t.,1h.
to a solution of 1.88g of lithocholic acid in 30mL of methanol was added 95mg of p-toluenesulfonic acid (p-TsOH), and the mixture was heated to 60 ℃ and stirred for 2 hours. After completion of the reaction, the reaction mixture was concentrated to remove the solvent, dissolved in 100mL of ethyl acetate, washed with saturated aqueous sodium bicarbonate and saturated brine in this order, dried over anhydrous sodium sulfate, filtered to remove sodium sulfate, and concentrated to give a crude product, which was dissolved in a mixed solvent of 3mL of DMF and 5mL of THF, to which 680mg of imidazole, 64mg of DMAP and 1.5g of TBSCl were added, followed by stirring at room temperature for 1 hour. After the reaction, 20mL of saturated sodium bicarbonate solution is added to quench the reaction, an organic phase is separated, an aqueous phase is extracted three times by dichloromethane, the organic phase is merged, the saturated sodium bicarbonate solution and the saturated sodium chloride solution are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent n-hexane: ethyl acetate: 100:1) to yield pure intermediate 27.
To a solution of 2.52g of intermediate 27 in 30mL of THF under ice bath was slowly added 570mg of lithium aluminum hydride (LiAlH)4) The reaction was heated to 50 ℃ for 1 hour. After the reaction is finished, 30mL of saturated ammonium chloride solution is carefully added in an ice bath to quench the reaction, an organic phase is separated, an aqueous phase is extracted three times by dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt solution are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 20:1) to yield pure intermediate 28.
1.43g of intermediate 28, 1.01g of triethylamine and 37mg of DMAP were dissolved in 30mL of DCM, 1.14g of TsCl was added, and the mixture was stirred at room temperature for 1 hour. After the reaction is finished, 30mL of saturated sodium bicarbonate solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by dichloromethane, the organic phase is merged, the saturated sodium bicarbonate solution and the saturated sodium chloride solution are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent n-hexane: ethyl acetate: 20:1) to yield pure intermediate 29.1H NMR(500MHz,CDCl3), (ppm)0.06(s,6H,CH3),0.59(s,3H,CH3),0.84(d,J＝6.5Hz,3H,CH3),0.89(s,12H,CH3), 0.92-1.55(m,24H,CH2and CH),1.63-1.85(m,5H,CH2),1.89-1.93(m,1H,CH2),2.45(s,3H, CH3),3.55-3.61(m,1H,CH2),3.96-4.04(m,2H,CH2),7.34(d,J＝8.0Hz,2H,CH),7.79(d,J＝8.0Hz,2H,CH)；13C NMR(125MHz,CDCl3),(ppm)-4.6,12.0,18.3,18.4,20.8,21.6,23.4,24.2,25.5,26.0,26.4,27.3,28.2,31.0,31.4,34.5,35.2,35.5,35.8,36.9,40.1,40.2,42.2,42.6,56.0, 56.3,71.2,72.8,127.8,129.7,133.3,144.5.
To a solution of 58mg of 1-propargyldiglycol in 5mL of THF was added 24mg of NaH (60%), followed by stirring at room temperature for 15 minutes, followed by addition of 126mg of intermediate 29, and heating under reflux for 6 hours. After the reaction is finished, 10mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was separated by column chromatography (200-300 mesh silica gel, eluent n-hexane: ethyl acetate: 3:1) to yield pure intermediate 30.1H NMR(500MHz,CDCl3),(ppm)0.06(s,6H,CH3),0.63(s,3H,CH3),0.89-0.91(m,15H,CH3), 0.92-1.68(m,27H,CH2and CH),1.73-1.85(m,4H,CH2),1.92-1.96(m,1H,CH2),2.43(t,J＝2.5Hz,1H,CH),3.40-3.44(m,2H,CH2),3.54-3.60(m,3H,CH2and CH),3.64-3.66(m,2H,CH2),3.68-3.72(m,4H,CH2),4.21(d,J＝2.5Hz,2H,CH2)；13C NMR(125MHz,CDCl3),(ppm)-4.6,12.0,18.3,18.6,20.8,23.4,24.2,25.9,26.1,26.4,27.3,28.2,31.0,32.0,34.5,35.54,35.55,35.8, 36.9,40.11,40.17,42.2,42.6,56.1,56.4,58.4,69.1,70.0,70.4,70.6,72.0,72.8,74.4,79.6.
To a solution of 60mg of intermediate 30 in 2mL of THF was added 0.6mL of a THF solution of 1M tetrabutylammonium fluoride (TBAF), and the mixture was stirred at room temperature for 1 hour. Concentrating after the reaction is finished, and performing column chromatography (200-300 mesh silica gel, eluent is n-hexane: ethyl acetate)1:1) was isolated to yield pure intermediate TC 558.1H NMR(500MHz,CDCl3),(ppm)0.64(s,3H, CH3),0.90-0.91(m,6H,CH3),0.96-1.56(m,22H,CH2and CH),1.64-1.66(m,2H,CH2),1.72-1.84 (m,4H,CH2),1.95-1.97(m,1H,CH2),2.44(t,J＝2.5Hz,1H,CH),3.39-3.44(m,2H,CH2), 3.59-3.65(m,5H,CH2and CH),3.69-3.70(m,4H,CH2),4.20-4.21(m,2H,CH2)；13C NMR(125 MHz,CDCl3),(ppm)11.9,18.5,20.7,23.3,24.1,26.0,26.3,27.1,28.2,30.4,31.9,34.5,35.3,35.5,35.7,36.3,40.1,40.3,42.0,42.6,56.0,56.4,58.3,69.0,70.0,70.3,70.5,71.7,71.9,74.5,79.5； HRMS calcd for C31H52O4[M+Na]+:511.3758；found:511.3677.
Figure BDA0001798453550000431
The reaction equation shown above is a synthetic route of TC828, and the reaction conditions are specifically as follows:
(a)Et3SiCl,imidazole,THF/DMF,r.t.,1h；
(b)I2,PPh3,imidazole,THF/DCM,0℃ to r.t.,1h；
(c)3,4-dihydro-2H-pyran,p-TsOH,DCM,0℃ to r.t.,1h；
(d)i.n-BuLi,HMPA,THF,-78℃ to 0℃,1h；ii.TBAF,THF,r.t.,1h；
(e)3-bromo-1-propyne,NaH(60％),THF,50℃,2h；
(f)i.n-BuLi,THF,-78℃,1h；ii.TMSCl,-78℃ to 0℃,1h；
(g)p-TsOH,MeOH,r.t.,1h；
(h)CBr4,PPh3,DCM,-10℃ to r.t.,6h；
(i)magnesium,THF,reflux,3h；
(j)TBAF,THF,r.t.,2h.
8.48g of diethylene glycol and 2.0g of imidazole were dissolved in a mixed solvent of 20mL of DMF and 30mL of THF, and 2.92g of triethylchlorosilane (Et) was slowly added dropwise to the solution in ice bath3SiCl) in 20mL of THF, and stirring at room temperature for 1 hour after the addition. After the reaction is finished, 100mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane and is merged into the organic phase, the organic phase is washed by the saturated ammonium chloride aqueous solution and the saturated common salt solution in sequence, then the mixture is dried by anhydrous sodium sulfate, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent n-hexane: ethyl acetate: 3:1) to yield pure intermediate 31.
4.4g of intermediate 31, 1.7g of imidazole and 5.5g of triphenylphosphine (PPh)3) Dissolved in 100mL DCM, and 5.08g of elemental iodine (I) was slowly added dropwise to the solution under ice-bath2) 30mL of THF, and stirring at room temperature for 1 hour after the completion of the dropwise addition. After the reaction is finished, 100mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane and is merged into the organic phase, the organic phase is washed by the saturated ammonium chloride aqueous solution and the saturated common salt solution in sequence, then the mixture is dried by anhydrous sodium sulfate, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent n-hexane: ethyl acetate: 10:1) to yield pure intermediate 32.
1.0g p-TsOH and 4.2g 3, 4-dihydro-2H-pyran (DHP) were added to a solution of 3.5g 3-butyn-1-ol in 100mL DCM at 0 ℃ and stirred at room temperature for 1 hour. After the reaction is finished, 100mL of saturated sodium bicarbonate solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by dichloromethane, the organic phase is merged, the saturated sodium bicarbonate solution and the saturated sodium chloride solution are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent n-hexane: ethyl acetate: 20:1) to yield pure intermediate 33.
In a dry, nitrogen-filled reaction flask, 3.08g of intermediate 33 were dissolved in 100mL of anhydrous THF, and 8.3mL of 2.4M n-butyllithium (n-BuLi) was slowly added dropwise to the solution at-78 deg.C and stirred for 0.5 hour. At this temperature, 3.58g of hexamethylphosphoric triamide (HMPA) and 4.95g of 32 were added in this order, and the mixture was heated to 0 ℃ and stirred for 1 hour. After the reaction is finished, 100mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated,the aqueous phase was extracted three times with dichloromethane, the organic phase was combined, washed successively with saturated aqueous ammonium chloride solution and saturated brine, then dried over anhydrous sodium sulfate, filtered to remove sodium sulfate, concentrated, redissolved with 100mL of tbhf, added 30mL of a 1M THF solution of TBAF, and stirred at room temperature for 1 hour. After the reaction is finished, the crude product is concentrated, and the pure intermediate 34 is obtained by separating the crude product by column chromatography (200-mesh silica gel with 300 meshes, and the eluent is n-hexane: ethyl acetate: 3: 1). HRMScalcd for C13H22O4[M+Na]+:265.1410；found:265.1413.
292mg of NaH (60%) was added to a solution of 1.37g of intermediate 34 in 40mL of THF, and the mixture was stirred at room temperature for 15 minutes, followed by addition of 2.38g of 3-bromopropyne and heating to 50 ℃ for reaction for 2 hours. After the reaction is finished, 100mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane and is merged into the organic phase, the organic phase is washed by the saturated ammonium chloride aqueous solution and the saturated common salt solution in sequence, then the mixture is dried by anhydrous sodium sulfate, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 8:1) to yield pure intermediate 35. HRMScalcd for C16H24O4[M+Na]+:303.1567；found:303.1597.
In a dry, nitrogen-filled reaction flask, 1.24g of intermediate 35 were dissolved in 20mL of anhydrous THF, and 3.0mL of 1.6M n-butyllithium (n-BuLi) was slowly added dropwise to the solution at-78 ℃ and stirred for 0.5 hour. At this temperature 0.53 g of trimethylchlorosilane (TMSCl) was added and the temperature was slowly raised to 0 ℃ and stirring was continued for 1 hour. And after the reaction is finished, adding 50mL of saturated ammonium chloride solution to quench the reaction, separating an organic phase, extracting the water phase for three times by using dichloromethane, merging the organic phase, washing the organic phase by using saturated ammonium chloride aqueous solution and saturated common salt water in sequence, drying the organic phase by using anhydrous sodium sulfate, filtering the mixture to remove the sodium sulfate, and concentrating the filtrate to obtain a crude product. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent n-hexane: ethyl acetate: 8:1) to yield pure intermediate 36.
To a solution of 915mg of intermediate 36 in 30mL of methanol was added 57mg of p-TsOH, and the mixture was stirred at room temperature for 1 hour. After the reaction, the solvent was removed by concentration, and methylene chloride was usedRedissolved, washed with saturated aqueous sodium bicarbonate and saturated brine in that order, then dried over anhydrous sodium sulfate, filtered to remove sodium sulfate, and concentrated to give the crude product. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate 5:1) to yield pure intermediate 37. HRMS calcd for C14H24O3[M+Na]+:291.1387；found:291.1398.
402mg of intermediate 37 and 996mg of carbon tetrabromide (CBr)4) Dissolved in 15mL DCM and 786mg PPh was slowly added dropwise to this solution at-10 deg.C3After the addition, the temperature was slowly raised to room temperature and stirred for 6 hours. And after the reaction is finished, adding 30mL of saturated ammonium chloride solution to quench the reaction, separating an organic phase, extracting the water phase for three times by using dichloromethane, merging the organic phase, washing the organic phase by using saturated ammonium chloride aqueous solution and saturated common salt water in sequence, drying the organic phase by using anhydrous sodium sulfate, filtering the mixture to remove the sodium sulfate, and concentrating the filtrate to obtain a crude product. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 10:1) to yield pure intermediate 38.1H NMR(500MHz,CDCl3),(ppm)0.18(s,9H,CH3), 2.44-2.48(m,2H,CH2),2.70-2.73(m,2H,CH2),3.41(t,J＝7.5Hz,2H,CH2),3.59(t,J＝7.5Hz, 2H,CH2),3.65-3.69(m,4H,CH2),4.21(s,2H,CH2)；13C NMR(125MHz,CDCl3),(ppm) -0.2,20.0,23.3,30.0,59.2,68.9,69.6,70.1,78.1,79.0,91.4,101.3；HRMS calcd for C14H23BrO2Si [M+Na]+:353.0543；found:353.0542.
192mg of magnesium turnings were added to a dry, nitrogen-filled reaction flask. 1.32g of intermediate 38 was dissolved in 5mL of anhydrous THF, about 1/4 of this solution was added to the magnesium turnings, 1 drop of 1, 2-dibromoethane was added and appropriate heating initiated the formation of Grignard reagent. After the initiation is successful, the residual bromide solution is dripped into the magnesium chips, and the dripping speed is controlled to keep the reaction liquid slightly boiling. After the addition, the heating and refluxing were continued for 2 hours. The reaction liquid is cooled for use.
430mg of intermediate 1 was dissolved in 5mL of anhydrous THF in a dry, nitrogen-filled reaction flask5mL of the above Grignard reagent in THF was added dropwise to the solution, and the mixture was stirred at room temperature for 3 hours. And after the reaction is finished, adding 30mL of saturated ammonium chloride solution to quench the reaction, separating an organic phase, extracting the water phase for three times by using dichloromethane, merging the organic phase, washing the organic phase by using saturated ammonium chloride aqueous solution and saturated common salt water in sequence, drying the organic phase by using anhydrous sodium sulfate, filtering the mixture to remove the sodium sulfate, and concentrating the filtrate to obtain a crude product. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 7:1) to yield pure intermediate 39.1H NMR(500MHz,CDCl3),(ppm)0.12(s,15H,CH3),0.79(s,3H,CH3),0.83(s,9H,CH3), 0.86-0.91(m,1H,CH2),0.94(s,3H,CH3),0.98-1.18(m,4H,CH2and CH),1.21(s,3H,CH3), 1.29-1.83(m,21H,CH2and CH),1.89-1.93(m,1H,CH2),2.02-2.23(m,9H,CH2),2.38-2.40(m, 5H,CH2),3.38-3.45(m,1H,CH),3.49-3.53(m,2H,CH2),3.59-3.63(m,2H,CH2),4.15(s,2H,CH2),5.25-5.26(m,1H,CH)；13C NMR(125MHz,CDCl3),(ppm)-4.6,0.2,13.45,13.52,18.16,18.22,19.3,20.0,20.8,22.4,23.7,25.5,25.8,27.9,31.2,31.7,32.0,36.5,37.3,40.1,41.8, 42.6,42.7,50.0,56.8,58.6,59.1,68.9,69.8,69.9,72.5,74.7,76.7,76.9,80.9,81.4,91.3,101.3, 120.9,141.4.
To a solution of 68mg of intermediate 39 in 2mL of THF was added 0.6mL of a THF solution of 1M tetrabutylammonium fluoride (TBAF), and the mixture was stirred at room temperature for 1 hour. After the reaction is finished, the intermediate TC828 is concentrated and separated by column chromatography (200-300 mesh silica gel, eluent is n-hexane: ethyl acetate-1: 1) to obtain pure intermediate TC 828.1H NMR(600MHz,CDCl3),(ppm)0.85(s,3H, CH3),0.87-0.99(m,2H,CH2),1.01(s,3H,CH3),1.04-1.23(m,3H,CH2and CH),1.27(s,3H, CH3),1.40-1.85(m,17H,CH2and CH),1.96-1.99(m,1H,CH2),2.08-2.10(m,1H,CH2),2.14-2.31 (m,4H,CH2),2.43-2.45(m,3H,CH2),3.49-3.58(m,3H,CH2and CH),3.65-3.66(m,2H,CH2), 3.69-3.71(m,2H,CH2),4.22(d,J＝1.2Hz,2H,CH2),5.35-5.36(m,1H,CH)；13C NMR(150 MHz,CDCl3),(ppm)13.5,13.6,19.3,20.0,20.9,22.4,23.7,25.5,31.2,32.5,31.7,36.4,37.2,40.1,41.8,42.2,42.7,49.9,56.8,58.4,58.6,69.0,69.9,70.0,71.7,74.5,74.8,76.9,79.6,81.5,91.3, 121.5,140.7；HRMS calcd for C32H48O4[M+Na]+:519.3445；found:519.3450.
Figure BDA0001798453550000471
The reaction equation shown above is a synthetic route of TC599 and its homologues, and the reaction conditions are as follows:
(a)Pd(PPh3)4,Na2CO3,toluene/H2O,90℃,5h；
(b)Boc2O,DCM,r.t.,2h；
(c)LiAlH4,THF,reflux,2h；
(d)i,PhCHO,toluene,reflux,6h；ii,Boc2O,r.t.,1h；iii,1M KHSO4,r.t.,1h；
(e)NaBH4,MeOH,40℃,1h；
(f)HATU,DIPEA,DCM,40℃,12h；
(g)oligo ethylene glycol,NaH(60％),THF,60℃,4-6h；
(h)DPPA,DBU,THF,r.t.to reflux,18-24h；
(i)2N HCl in dioxane,r.t.,2h.
to a dry nitrogen-filled reaction flask were added 4.4g of 2-fluoro-4-bromopyridine, 3.94g of 3-formylphenylboronic acid, 577mg of tetrakis (triphenylphosphine) palladium, 6.1g of sodium hydrogencarbonate, 50mL of toluene and 100mL of water, and the mixture was heated to 90 ℃ and stirred for 5 hours. And after the reaction is finished, adding 50mL of saturated ammonium chloride solution to quench the reaction, separating an organic phase, extracting the water phase for three times by using dichloromethane, merging the organic phase, washing the organic phase by using saturated ammonium chloride aqueous solution and saturated common salt water in sequence, drying the organic phase by using anhydrous sodium sulfate, filtering the mixture to remove the sodium sulfate, and concentrating the filtrate to obtain a crude product. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 20:1) to yield pure intermediate 40.1H NMR(500MHz,CDCl3),δ(ppm)7.19(s,1H,CH), 7.46-7.47(m,1H,CH),7.71(t,J＝7.5Hz,1H,CH),7.90-7.92(m,1H,CH),7.99-8.01(m,1H,CH), 8.15-8.16(m,1H,CH),8.33(d,J＝5.0Hz,1H,CH),10.12(s,1H,CH)；13C NMR(125MHz, CDCl3),δ(ppm)107.3(d,J＝38.0Hz),119.4(d,J＝4.1Hz),127.7,130.0,131.0,132.7,137.1,138.0(d,J＝3.4Hz),148.3(d,J＝15.4Hz),152.5(d,J＝8.2Hz),164.4(d,J＝237.4Hz),191.5.
To a solution of 22.8g of trans 1, 4-cyclohexanediamine in 200mL of DCM was added 10.8 di-tert-butyl dicarbonate (Boc)2O), stirred at room temperature for 2 hours. After the reaction is finished, the intermediate 41 is concentrated and separated by column chromatography (200-300 mesh silica gel, eluent dichloromethane: methanol: 7:1) to obtain pure intermediate.
To a solution of 2.1g of intermediate 41 in 50mL of THF was added 1.8g of LiAlH4And heated under reflux for 2 hours. After the reaction is finished, 50mL of saturated ammonium chloride solution is carefully added in an ice bath to quench the reaction, an organic phase is separated, an aqueous phase is extracted three times by dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt solution are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent dichloromethane: methanol: 3:1) to yield pure intermediate 42.
12.8g of intermediate 42 and 10.6g of benzaldehyde are dissolved in 50mL of toluene and heated under reflux for 6 hours, and the water formed in the reaction is separated off using a water separator. Then cooled to room temperature and the trap was removed and 22g of di-tert-butyl dicarbonate (Boc) was added2O), stirred at room temperature for 1 hour. Then, 50mL of a 1M aqueous potassium hydrogensulfate solution was added, and the mixture was stirred at room temperature for 1 hour. After the reaction is finished, liquid separation is carried out, the water phase is washed by ethyl acetate for 2 times, then 6M sodium hydroxide aqueous solution is added to adjust the pH value to be more than 12, the mixture is extracted by ethyl acetate for 3 times, the extracted organic phase is washed by saturated sodium chloride solution, dried by anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent dichloromethane: methanol: 10:1) to yield pure intermediate 43.
2.9g of 40 and 3.0g of intermediate 43 were dissolved in 50mL of methanol, heated to 40 ℃ and stirred for 0.5 hour. 760mg of boron are added to this solution in portionsSodium hydride (NaBH)4) Stirring was continued at 40 ℃ for 0.5 hour. After the reaction is finished, 150mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt solution are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent dichloromethane: methanol: 50:1) to yield pure intermediate 44.1H NMR(500MHz,CDCl3),δ(ppm)1.24-1.51(m,4H,CH2),1.46(s,3H,CH3), 1.70-1.74(m,3H,CH2and CH),2.04-2.07(m,2H,CH2),2.44-2.49(m,1H,CH),2.70(s,3H,CH3), 3.89(s,2H,CH2),7.14(br,1H,CH),7.40-7.47(m,3H,CH),7.50-7.53(m,1H,CH),7.60(m,1H, CH),8.24-8.26(m,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)28.4,32.4,51.0,55.7,79.2, 107.0(d,J＝37.5Hz),119.5(d,J＝3.9Hz),125.5,126.6,129.2,129.3,137.1,141.8,147.8(d,J＝ 15.4Hz),153.9(d,J＝8.1Hz),155.5,164.4(d,J＝236.7Hz).HRMS calcd forC24H32FN3O2[M+H]+:414.2551；found:414.2557.
2.55g of 3-chlorobenzo [ b ]]Thiophene-2-carboxylic acid and 5.7g O- (7-Azobenzotriazole) -N, N, N, N-tetramethyluronium Hexafluorophosphate (HATU) were dissolved in 25mL of DCM and stirred at room temperature for 0.5 hour. To this solution was added a solution of 4.13g intermediate 44 and 3.22g Diisopropylethylamine (DIPEA) in 25mL DCM, heated to 40 ℃ and stirred overnight. And after the reaction is finished, adding 50mL of saturated ammonium chloride solution to quench the reaction, separating an organic phase, extracting the water phase for three times by using dichloromethane, merging the organic phase, washing the organic phase by using saturated ammonium chloride aqueous solution and saturated common salt water in sequence, drying the organic phase by using anhydrous sodium sulfate, filtering the mixture to remove the sodium sulfate, and concentrating the filtrate to obtain a crude product. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 3:1) to yield pure intermediate 45.1H NMR(500MHz,CDCl3),δ(ppm)1.24-1.51(m,4H,CH2),1.46(s,3H,CH3), 1.70-1.74(m,3H,CH2and CH),2.04-2.07(m,2H,CH2),2.44-2.49(m,1H,CH),2.70(s,3H,CH3),3.89(s,2H,CH2),7.14(br,1H,CH),7.40-7.47(m,3H,CH),7.50-7.53(m,1H,CH),7.60(m,1H, CH),8.24-8.26(m,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)28.4,32.4,51.0,55.7,79.2, 107.0(d,J＝37.5Hz),119.5(d,J＝3.9Hz),125.5,126.6,129.2,129.3,137.1,141.8,147.8(d,J＝ 15.4Hz),153.9(d,J＝8.1Hz),155.5,164.4(d,J＝236.7Hz)；HRMScalcd for C33H35ClFN3O3S [M+Na]+:630.1964；found:630.1955.
General procedure for the synthesis of TC599 and homologs:
to a solution of 186mg of ethylene glycol in 10mL of THF was added 60mg of NaH (60%), followed by stirring at room temperature for 15 minutes, then intermediate 45 was added, and the reaction was heated to 60 ℃ for 6 hours. After the reaction is finished, 20mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate 1:1) to yield pure intermediate 46.1H NMR (500MHz,CDCl3),δ(ppm)1.32-1.44(m,11H,CH3and CH2),1.63-1.72(m,4H,CH2),1.84-1.96 (m,2H,CH2),2.57 and 2.70(s,3H,CH3),3.75-3.98(m,3H,CH2and CH),4.49-4.50(m,2H,CH2),4.66and 4.84(s,2H,CH2),6.85-7.24(m,2H,CH),7.30-7.52(m,5H,CH),7.67-7.89(m,3H,CH), 8.12-8.16(m,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)13.9,20.7,28.1,30.5,38.2,44.8, 52.4,58.5,60.1,61.7,68.4,79.2,108.6,115.4,118.7,122.2,122.5,125.17,125.23,125.33,126.2, 127.3,129.0,129.7,135.4,136.9,138.0,138.8,146.5,151.1,155.1,163.3,164.2,170.8；HRMS calcd for C35H40ClN3O5S[M+H]+:650.2450；found:650.2439.
Intermediate 47.1H NMR(600MHz,CDCl3),δ(ppm)1.25-1.43(m,10H,CH2),1.63-1.73(m,4H, CH2),1.85-1.96(m,2H,CH2),2.57and 2.70(s,3H,CH3),3.68-3.70(m,2H,CH2),3.77(t,J＝4.8 Hz,2H,CH2),3.89-3.90(m,2H,CH2),4.54-4.55(m,2H,CH2),4.67and 4.84(s,2H,CH2), 6.87-7.23(m,2H,CH),7.32-7.55(m,5H,CH),7.69-7.71(m,1H,CH),7.82-7.92(m,2H,CH), 8.15-8.19(m,1H,CH)；13C NMR(150MHz,CDCl3),δ(ppm)28.3,30.7,45.0,52.6,58.7,61.6, 65.1,69.6,72.4,79.4,108.7,115.4,115.6,119.0,122.5,122.7,125.4,125.6,126.4,127.2,127.5, 129.1,129.9,135.6,137.2,138.2,138.9,147.0,151.1,155.4,163.5,164.1；HRMS calcd for C37H44ClN3O6S[M+H]+:694.2712；found:694.2712.
Intermediate 48.1H NMR(600MHz,CDCl3),δ(ppm)1.26-1.44(m,10H,CH2),1.64-1.73(m,4H, CH2),1.85-1.96(m,2H,CH2),2.57and 2.71(s,3H,CH3),3.61(t,J＝4.8Hz,2H,CH2),3.69-3.79 (m,6H,CH2),3.89-3.91(m,2H,CH2),4.54-4.55(m,2H,CH2),4.67and 4.84(s,2H,CH2), 6.87-7.22(m,2H,CH),7.32-7.55(m,5H,CH),7.69-7.71(m,1H,CH),7.82-7.92(m,2H,CH), 8.14-8.18(m,1H,CH)；13C NMR(150MHz,CDCl3),δ(ppm)28.3,29.4,30.8,45.0,52.6,58.7, 61.6,65.1,69.6,70.2,70.6,72.5,79.4,108.7,115.3,115.5,119.0,122.5,122.7,125.4,125.6,126.4, 127.2,127.4,129.1,129.9,135.6,137.2,138.3,138.9,146.9,151.0,155.4,163.5,164.1；HRMS calcd for C39H48ClN3O7S[M+H]+:738.2974；found:738.2976.
Intermediate 49.1H NMR(500MHz,CDCl3),δ(ppm)1.25-1.53(m,4H,CH2),1.46(s,9H,CH3), 1.53-1.96(m,6H,CH2and CH),2.70(s,3H,CH3),3.60-3.76(m,16H,CH2),3.91(s,2H,CH2), 6.89-6.95(m,1H,CH),7.11(br,1H,CH),7.46-7.53(m,3H,CH),7.70(br,1H,CH),7.82-7.92(m, 2H,CH),8.16-8.22(m,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)28.4,61.7,69.6,70.3,70.6, 72.5,99.9,119.0,125.5,125.7,126.5,129.3,137.2,163.6；HRMScalcd for C41H52ClN3O8S [M+H]+:782.3236；found:782.3226.
325mg of intermediate 46, 550mg of Diphenylphosphorylazide (DPPA) and 228mg of 1, 8-diazabicycloundecen-7-ene (DBU) were dissolved in 5mL of THF, stirred at room temperature for 6 to 12 hours, and after completion of disappearance of 46 by TLC, heating and refluxing were continued for 12 hours. After the reaction is finished, 20mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 3:1) to yield pure intermediate 50.1H NMR(500MHz,CDCl3),δ(ppm) 1.26-1.43(m,4H,CH2),1.40(s,9H,CH3),1.64-1.96(m,6H,CH2and CH),2.70(s,3H,CH3), 3.61-3.78(m,2H,CH2),3.90-3.92(m,2H,CH2),4.15-4.20(m,2H,CH2),6.89-6.96(m,1H,CH), 7.13(br,1H,CH),7.47-7.54(m,3H,CH),7.70(br,1H,CH),7.82-7.93(m,2H,CH),8.12-8.24(m, 1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)14.0,20.8,28.1,29.2,30.6,44.8,49.0,49.3,53.3,58.5,60.1,79.1,105.4,116.8,118.8,122.3,122.5,124.9,125.3,126.3,127.8,129.0,129.7,135.4, 137.0,137.3,137.9,138.8,151.9,155.2,162.3,163.4,170.8；HRMS calcdfor C35H39ClN6O4S [M+H]+:675.2515；found:675.2512.
Intermediate 51.1H NMR(500MHz,CDCl3),δ(ppm)1.26-1.30(m,4H,CH2),1.41(s,9H,CH3), 1.66-1.96(m,6H,CH2and CH),2.71(s,3H,CH3),3.38(t,J＝5.0Hz,2H,CH2),3.67-3.77(m,4H, CH2),3.91(t,J＝5.0Hz,2H,CH2),4.53-4.55(m,2H,CH2),4.83(s,3H,CH3),6.86-7.14(m,2H, CH),7.44-7.51(m,4H,CH),7.69(br,1H,CH),7.82-7.91(m,2H,CH),8.09-8.18(m,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)28.2,30.6,44.9,50.5,53.3,58.6,60.6,65.0,65.9,69.5,69.8, 79.3,98.5,108.6,115.4,119.9,120.0,125.2,125.4,125.9,126.3,129.0,129.7,129.9,137.0,146.8, 149.5,149.6,150.2,164.0；HRMS calcdfor C37H43ClN6O5S[M+H]+:719.2777；found:719.2772.
An intermediate body 52.1H NMR(500MHz,CDCl3),δ(ppm)1.26-1.30(m,4H,CH2),1.41(s,9H,CH3), 1.66-1.96(m,6H,CH2and CH),2.71(s,3H,CH3),3.38(t,J＝5.0Hz,2H,CH2),3.67-3.77(m,8H, CH2),3.91(t,J＝5.0Hz,2H,CH2),4.53-4.55(m,2H,CH2),4.83(s,3H,CH3),6.86-7.14(m,2H, CH),7.44-7.51(m,4H,CH),7.69(br,1H,CH),7.82-7.91(m,2H,CH),8.09-8.18(m,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)28.3,30.7,45.0,50.5,58.6,65.1,69.7,69.9,70.6,79.3,108.7, 115.4,118.9,122.7,125.3,126.4,129.1,137.1,138.4,146.9,155.3,164.2；HRMS calcd for C39H47ClN6O6S[M+H]+:763.3039；found:763.3039.
Intermediate 53.1H NMR(500MHz,CDCl3),δ(ppm)1.26-1.43(m,4H,CH2),1.40(s,9H,CH3), 1.64-1.96(m,6H,CH2and CH),2.70(s,3H,CH3),3.61-3.78(m,16H,CH2),3.90-3.92(m,2H, CH2),4.15-4.20(m,2H,CH2),6.89-6.96(m,1H,CH),7.13(br,1H,CH),7.47-7.54(m,3H,CH), 7.70(br,1H,CH),7.82-7.93(m,2H,CH),8.12-8.24(m,1H,CH)；13C NMR(125MHz,CDCl3),δ (ppm)28.3,50.5,61.0,61.6,63.6,66.0,67.0,69.9,70.5,70.6,72.2,72.6,98.7,119.0,125.5,126.5, 129.3；HRMS calcd for C41H51ClN6O7S[M+H]+:807.3301；found:807.3310.
To 2mL of dioxane solution of 134mg of intermediate 50 was added 2mL of 4M HCl in dioxane solution, and the mixture was stirred at room temperature for 2 hours. After the reaction is finished, the intermediate TC599 is obtained by concentration and column chromatography (200-300 mesh silica gel, the eluent is dichloromethane: methanol: 30: 1).1H NMR(600MHz,CD3OD),δ(ppm)1.07-1.13(m,2H,CH2), 1.68-1.81(m,4H,CH2),1.94-2.07(m,2H,CH2),2.42 and 2.52(s,3H,CH3),2.81-2.90(m,1H,CH),31.8-3.19(m,1H,CH),3.41-3.43(m,1H,CH),3.54-3.58(m,2H,CH2),3.65-3.72(m,1H,CH),4.03-4.05(m,2H,CH2),4.20 and 4.55(s,2H,CH2),6.31-6.66(m,2H,CH),7.15-7.49(m,6H, CH),7.57-7.85(m,3H,CH)；13C NMR(150MHz,CD3OD),δ(ppm)28.9,30.4,31.0,46.4,50.4, 50.8,57.5,60.1,62.4,64.5,73.5,107.9,116.9,120.3,123.6,124.5,126.6,126.9,127.4,128.4, 129.8,130.8,131.1,136.8,138.68,138.74,140.8,154.6,164.9,165.7；HRMS calcd for C30H31ClN6O2S[M+H]+:575.1990；found:575.1993.
TC600。1H NMR(600MHz,CD3OD),δ(ppm)1.18-1.31(m,2H,CH2),1.80-2.21(m,6H,CH2),2.54 and 2.65(s,3H,CH3),2.90-2.97(m,1H,CH),3.32-3.34(m,1H,CH),3.39-3.40(m,2H, CH2),3.76(t,J＝4.8 Hz,2H,CH2),3.89-3.91(m,2H,CH2),4.50 and 4.72(s,2H,CH2),6.82-7.18 (m,3H,CH),7.24-7.32(m,2H,CH),7.49-7.63(m,4H,CH),7.79-7.82(m,1H,CH),7.91-8.01(m, 2H,CH),8.10-8.19(m,1H,CH)；13C NMR(150MHz,CD3OD),δ(ppm)27.4,28.8,29.4,44.8, 50.4,55.9,58.6,60.8,65.3,69.2,69.9,72.1,108.1,115.2,118.7,119.9,120.0,122.0,122.9,123.2, 125.1,125.4,125.8,126.8,127.5,128.9,129.1,129.4,135.2,137.2,138.2,139.0,146.9,151.4, 152.71,152.75,164.2,164.5；HRMS calcd for C32H35ClN6O3S[M+H]+:619.2253；found: 619.2251.
TC801。1H NMR(500MHz,CDCl3and CD3OD),δ(ppm)1.24-1.34(m,2H,CH2), 1.81-2.23(m,6H,CH2),2.56 and 2.66(s,3H,CH3),2.97-3.00(m,1H,CH),3.32-3.37(m,2H,CH2),3.63-3.92(m,10H,CH2),4.49 and 4.73(s,2H,CH2),6.85-7.24(m,2H,CH),7.34-7.59(m, 5H,CH),7.76-7.97(m,3H,CH),8.11-8.17(m,1H,CH)；13C NMR(125MHz,CDCl3andCD3OD), δ(ppm)26.7,28.2,28.8,49.7,58.0,62.2,64.6,68.8,69.1,69.6,69.7,107.6,109.2,114.6,121.5, 122.2,125.0,126.1,126.8,128.4,136.4,137.4,146.0；HRMS calcdfor C34H39ClN6O4S[M+H]+: 663.2515；found:663.2509.
TC588。1H NMR(600MHz,CDCl3),δ(ppm)1.22-1.28(m,2H,CH2),1.85-2.23(m,6H,CH2and CH),2.58 and 2.68(s,3H,CH3),3.32-3.34(m,2H,CH2),3.61-3.89(m,16H,CH2),4.12-4.25(m,2H,CH2),4.46-4.49(m,2H,CH2),6.81-6.99(m,1H,CH),7.10(br,1H,CH),7.27-7.62(m,3H,CH),7.81-7.91(m,2H,CH),8.00-8.12(m,1H,CH)；13C NMR(150MHz,CDCl3),δ(ppm)28.3,50.5,61.0,61.6,63.6,66.0,67.0,69.9,70.5,70.6,72.2,72.6,98.7,119.0, 125.5,126.5,129.3；HRMS calcd for C36H43ClN6O5S[M+H]+:707.2777；found:707.2791.
Figure BDA0001798453550000531
The reaction equation shown above is a synthetic route of TC580, and the reaction conditions are specifically as follows:
(a)Pd(PPh3)4,Na2CO3,toluene/H2O,90℃,3-5h；
(b)NaBH4,MeOH,40℃,1h；
(c)HATU,DIPEA,DCM,40℃,12h；
(d)tetraethylene glycol,NaH(60％),THF,60℃,4-6h；
(e)DPPA,DBU,THF,r.t.to reflux,18-24h；
(f)2N HCl in dioxane,r.t.,2h.
to a dry nitrogen-filled reaction flask were added 4.4g of 2-fluoro-5-bromopyridine, 3.94g of 3-formylphenylboronic acid, 577mg of tetrakis (triphenylphosphine) palladium, 6.1g of sodium hydrogencarbonate, 50mL of toluene and 100mL of water, and the mixture was heated to 90 ℃ and stirred for 5 hours. And after the reaction is finished, adding 50mL of saturated ammonium chloride solution to quench the reaction, separating an organic phase, extracting the water phase for three times by using dichloromethane, merging the organic phase, washing the organic phase by using saturated ammonium chloride aqueous solution and saturated common salt water in sequence, drying the organic phase by using anhydrous sodium sulfate, filtering the mixture to remove the sodium sulfate, and concentrating the filtrate to obtain a crude product. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 20:1) to yield pure intermediate 54.
2.9g of intermediate 54 and 3.0g of 43 were dissolved in 50mL of methanol, heated to 40 ℃ and stirred for 0.5 hour. To this solution 760mg of sodium borohydride (NaBH) was added portionwise4) Stirring was continued at 40 ℃ for 0.5 hour. After the reaction is finished, 150mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt solution are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent dichloromethane: methanol: 50:1) to yield pure intermediate 55.1H NMR(500MHz,CDCl3),δ(ppm)1.26-1.48(m,4H,CH2),1.46(s,9H,CH3), 1.70-1.72(m,2H,CH2),2.06-2.09(m,2H,CH2),2.49-2.53(m,1H,CH),2.70(s,3H,CH3),3.24(br,1H,CH),3.89(s,2H,CH2),6.99(dd,J＝8.5,3.0Hz,1H,CH),7.37-7.43(m,3H,CH),7.54(s, 1H,CH),7.99(td,J＝8.0,2.5Hz,1H,CH),8.40(d,J＝2.5Hz,1H,CH),8.24-8.26(m,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)28.1,28.2,31.7,50.5,53.2,79.0,109.1(d,J＝37.3Hz), 125.5,126.7,127.8,129.0,134.4(d,J＝4.5Hz),136.5,139.5(d,J＝8.0Hz),140.5,145.5(d,J＝14.6Hz),155.3,162.8(d,J＝237.8Hz)；HRMS calcd for C24H32FN3O2[M+H]+:414.2551；found: 414.2556.
2.55g of 3-chlorobenzo [ b ]]Thiophene-2-carboxylic acid and 5.7g O- (7-Azobenzotriazole) -N, N, N, N-tetramethyluronium Hexafluorophosphate (HATU) were dissolved in 25mL of DCM and stirred at room temperature for 0.5 hour. To this solution was added a solution of 4.13g of intermediate 55 and 3.22g of Diisopropylethylamine (DIPEA) in 25mL of DCM, heated to 40 ℃ and stirred overnight. After the reaction is finished, 50mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted by dichloromethane for three times, the organic phase is merged, and saturated ammonium chloride is sequentially usedThe aqueous solution and saturated brine were washed, then dried over anhydrous sodium sulfate, filtered to remove sodium sulfate, and concentrated to give a crude product. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 3:1) to yield pure intermediate 56.1H NMR(500MHz,CDCl3),δ(ppm)1.24-1.46(m,11H,CH2and CH3),1.64-1.74(m,5H,CH2and CH),1.87-1.97(m,2H,CH2),2.58 and 2.71(s,3H,CH3),3.78-3.87(m,2H,CH2),4.68and 4.84(s,2H,CH2),7.01-7.02(m,1H,CH),7.22-7.62(m,6H,CH),7.72-8.01(m,3H,CH), 8.26-8.45(m,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)14.1,20.9,28.3,28.5,29.5,30.8, 45.1,52.5,53.4,58.6,60.3,79.4,109.2(d,J＝37.4Hz),118.9,122.6(d,J＝31.8Hz),125.4,125.6, 126.4,129.3,136.8,137.1,139.7,145.7(d,J＝14.4Hz),155.3,163.0(d,J＝237.9Hz),163.5, 171.0；HRMS calcd for C33H35ClFN3O3S[M+Na]+:630.1964；found:630.1958.
60mg of NaH (60%) was added to a 10mL THF solution of 582mg of tetraethylene glycol, and the mixture was stirred at room temperature for 15 minutes, followed by addition of intermediate 56 and heating to 60 ℃ for reaction for 6 hours. After the reaction is finished, 20mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate 1:1) to yield pure intermediate 57. HRMS calcd for C41H52ClN3O8S[M+H]+:782.3236；found:782.3226.
391mg of intermediate 57, 550mg of Diphenylphosphorylazide (DPPA) and 228mg of 1, 8-diazabicycloundecen-7-ene (DBU) were dissolved in 5mL of THF, stirred at room temperature for 6 to 12 hours, and after completion of disappearance of 57 by TLC, heating and refluxing were continued for 12 hours. After the reaction is finished, 20mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted by dichloromethane for three times, the organic phase is merged, and saturated ammonium chloride is sequentially usedThe mixture was washed with saturated brine, dried over anhydrous sodium sulfate, filtered to remove sodium sulfate, and concentrated to give a crude product. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 3:1) to yield pure intermediate 58.1H NMR(600MHz,CDCl3),δ(ppm) 1.26-1.49(m,11H,CH3and CH2),1.59-1.96(m,6H,CH2),2.56-2.70(s,4H,CH3and CH), 3.50-3.68(m,2H,CH2),3.64-3.74(m,12H,CH2),3.88-3.89(m,2H,CH2),4.54(br,2H,CH2),4.66 and 4.84(s,2H,CH2),6.84-6.88(m,1H,CH),7.10-7.52(m,8H,CH),7.61-7.89(m,4H,CH), 8.26-8.40(m,1H,CH)；13C NMR(150MHz,CDCl3),δ(ppm)28.0,29.1,30.4,31.0,33.8,36.0, 40.0,42.4,44.8,50.2,58.4,64.9,69.2,69.6,70.21,70.24,70.9,79.0,110.8,118.6,119.8,120.0, 120.2,122.1,122.3,122.4,124.0,124.7,125.1,126.1,128.8,129.0,129.2,129.6,129.7,135.2, 136.8,137.0,137.1,137.7,144.4,155.0,162.1,162.6,163.1；HRMScalcd for C41H51ClN6O7S [M+H]+:807.3301；found:807.3313.
To 2mL of dioxane solution of 150mg of intermediate 58 was added 2mL of 4M HCl in dioxane solution, and the mixture was stirred at room temperature for 2 hours. After the reaction is finished, the intermediate TC580 is obtained by concentration and column chromatography (200-300 mesh silica gel, eluent is dichloromethane: methanol: 30: 1).1H NMR(600MHz,CDCl3),δ(ppm)1.13-1.45(m,2H,CH2), 1.74-2.15(m,6H,CH2),2.50and 2.60(s,3H,CH3),2.81-2.94(m,1H,CH),3.27-3.31(m,3H,CH2and CH),3.56-3.68(m,10H,CH2),3.74-3.84(m,3H,CH2and CH),4.43 and 4.64(s,2H,CH2), 6.80-7.22(m,3H,CH),7.30-7.62(m,6H,CH),7.76-7.95(m,2H,CH),8.14-8.35(m,1H,CH)；13C NMR(150MHz,CDCl3),δ(ppm)28.6,29.1,30.2,30.7,35.3,43.9,46.2,51.7,57.2,59.9,66.8, 70.6,71.0,71.46,71.58,71.64,112.1,120.0,121.0,121.3,121.6,123.3,124.2,124.6,126.0,126.4, 126.9,127.1,128.2,130.4,130.6,130.7,131.1,131.5,133.0,136.6,138.5,139.0,139.3,140.2, 145.5,162.4,162.6,164.5,165.5；HRMScalcd for C36H43ClN6O5S[M+H]+:707.2777；found: 707.2786.
Figure BDA0001798453550000561
The reaction equation shown above is a synthetic route of TC578, and the reaction conditions are specifically as follows:
(a)tetraethylene glycol,NaH(60％),DMF,120℃,12h；
(b)DPPA,DBU,THF,r.t.to reflux,18-24h.
60mg of NaH (60%) was added to a 10mL DMF solution of 582mg of tetraethylene glycol, and stirred at room temperature for 15 minutes, followed by addition of 512mg of LY2940680, and heating to 120 ℃ for reaction for 12 hours. After the reaction, 20mL of saturated ammonium chloride solution was added to quench the reaction, the reaction was extracted three times with dichloromethane, the organic phase was washed successively with saturated aqueous ammonium chloride solution and saturated brine, and then dried over anhydrous sodium sulfate, filtered to remove sodium sulfate, and concentrated to give a crude product. The crude product was isolated by column chromatography (200-300 mesh silica gel, eluent dichloromethane: methanol: 20:1) to yield pure intermediate 59.1H NMR(500MHz, CDCl3)majorrotamer,(ppm)1.76-2.26(m,4H,CH2),2.77(s,3H,CH3),3.37-3.39(m,2H, CH2),3.61(d,J＝4.0Hz,2H,CH2),3.67-3.75(m,12H,CH2),3.88-3.91(m,2H,CH2),4.06(s,3H, CH3),4.20-4.24(m,4H,CH2),4.90-4.94(m,1H,CH),6.60(d,J＝2.0Hz,1H,CH),7.17(d,J＝ 1.5Hz,1H,CH),7.25-7.39(m,2H,CH),7.66(d,J＝2.0Hz,1H,CH),7.82-7.91(m,2H,CH), 8.03-8.14(m,2H,CH)；minor rotamer,(ppm)1.76-2.24(m,4H,CH2),3.10(s,3H,CH3), 2.93-2.99(m,2H,CH2),3.49-3.52(m,1H,CH),3.61(d,J＝4.0Hz,2H,CH2),3.67-3.75(m,12H, CH2),3.88-3.91(m,2H,CH2),4.02(s,3H,CH3),4.11-4.18(m,4H,CH2),6.58(d,J＝2.0Hz,1H, CH),7.15(d,J＝1.5Hz,1H,CH),7.25-7.39(m,2H,CH),7.64(d,J＝2.0Hz,1H,CH),7.82-7.91 (m,2H,CH),8.03-8.14(m,2H,CH)；13C NMR(125MHz,CDCl3)major rotamer,20.9,27.4, 27.9,28.5,31.6,38.0,50.7,51.0,56.7,61.4,67.7,69.2,70.0,70.3,70.4,70.6,72.4,108.9,112.8(q, J＝4.5Hz),118.0,121.2,123.6(q,J＝272.2Hz),124.5,124.8(q,J＝2.5Hz),126.0,127.4(q,J＝ 31.4Hz),127.7,128.4,131.4,131.9,136.6,138.0,147.2,158.7,159.4,168.8,171.0；minor rotamer, (ppm)14.0,29.0,29.5,38.0,49.9,50.2,50.9,53.3,60.2,67.7,69.2,70.0,70.3,70.4,70.6, 72.4,109.0,113.0(q,J＝4.5Hz),117.9,121.2,123.6(q,J＝272.2Hz),124.0(q,J＝2.1Hz), 124.3,126.0,127.4(q,J＝31.4Hz),127.4,128.0,131.5,132.0,136.5,138.0,147.5,158.8,159.3, 168.7,171.0；HRMS calcdfor C34H41F3N6O6[M+H]+:687.3112；found:687.3135.
343mg of intermediate 59, 550mg of Diphenylphosphorylazide (DPPA) and 228mg of 1, 8-diazabicycloundecen-7-ene (DBU) were dissolved in 5mL of HF, stirred at room temperature for 6 to 12 hours, and after the complete disappearance of intermediate 59 was detected by TLC, heating and refluxing were continued for 12 hours. After the reaction is finished, 20mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was separated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate: 3:1) to yield pure intermediate TC 578.1H NMR(500MHz,CDCl3) major rotamer,(ppm)1.63-1.66(m,2H,CH2),1.74-2.27(m,4H,CH2),2.75(s,3H,CH3), 3.38-3.40(m,4H,CH2),3.66-3.74(m,10H,CH2),3.88-3.91(m,2H,CH2),4.06(s,3H,CH3), 4.19-4.22(m,4H,CH2),4.90-4.96(m,1H,CH),6.59(d,J＝2.0Hz,1H,CH),7.14(d,J＝1.5Hz, 1H,CH),7.24-7.27(m,2H,CH),7.66(d,J＝2.0Hz,1H,CH),7.80-7.89(m,2H,CH),8.04-8.12 (m,2H,CH)；minor rotamer,(ppm)1.63-1.66(m,2H,CH2),1.76-2.24(m,4H,CH2),3.10(s,3H, CH3),2.91-2.98(m,2H,CH2),3.47-3.54(m,1H,CH),3.66-3.74(m,10H,CH2),3.88-3.91(m,2H,CH2),4.02(s,3H,CH3),4.19-4.22(m,4H,CH2),6.58(d,J＝2.0Hz,1H,CH),7.13(d,J＝1.5Hz, 1H,CH),7.24-7.27(m,2H,CH),7.65(d,J＝2.0Hz,1H,CH),7.88-7.89(m,2H,CH),8.04-8.12 (m,2H,CH)；13C NMR(125MHz,CDCl3)major rotamer,27.2,27.7,28.4,28.8,29.2,31.4, 37.8,42.4,49.8,50.2,50.4,50.6,50.8,56.4,67.6,69.0,69.6,70.20,70.2170.24,70.4,70.9,108.7, 112.7(q,J＝4.5Hz),117.7,121.0,123.1(q,J＝272.2Hz),124.9,125.0(q,J＝2.5Hz),126.4, 127.4(q,J＝31.4Hz),127.7,128.3,129.4,131.2,131.7,136.4,137.7,147.0,158.5,159.2,168.6； minor rotamer,(ppm)14.0,29.0,29.5,37.8,49.9,50.2,50.9,53.3,60.2,67.7,69.2,70.0, 70.3,70.4,70.6,72.4,109.0,112.9(q,J＝4.5Hz),117.6,120.9,123.1(q,J＝272.2Hz),124.0(q,J ＝2.1Hz),124.3,126.3,127.4(q,J＝31.4Hz),127.4,128.3,129.2,131.3,131.8,136.3,137.7, 147.2,158.7,159.0,168.4；HRMS calcd for C34H40F3N9O5[M+H]+:712.3177；found:712.3178.
Figure BDA0001798453550000581
The reaction equation shown above is a synthetic route of TC1306, and the reaction conditions are specifically as follows:
(a)SOCl2,70℃,6h；
(b)i.thiourea,H2O,reflux,18h；ii.3M NaOH,reflux,3h；iii.HCl；
(c)K2CO3,DMF,r.t.,12h；
(d)DPPA,DBU,THF,r.t.to reflux,18-24h；
(e)aq.NaOH,reflux,12h；
(f)mCPBA,DCM,r.t.,1h；
(g)SnCl2,EtOH,pH<3,reflux,6h；
(h)HATU,DIPEA,DCM,r.t.,12h.
general procedure for the synthesis of TC1306 and homologs:
3.0g triethylene glycol in 20mL thionyl chloride (SOCl)2) Heated to 70 ℃ and stirred for 6 hours. After the reaction is finished, the crude product is obtained by concentration, and column chromatography (200-mesh and 300-mesh silica gel is used for washingThe remover is n-hexane: ethyl acetate 1:1) isolated to yield pure intermediate 60.
1.68g of intermediate 60 and 1.06g of thiourea were dissolved in 30mL of water and heated to reflux with stirring for 18 hours, then 10mL of 3M NaOH solution was added and reflux with stirring continued for 3 hours. After the reaction is finished, hydrochloric acid is added for neutralization reaction, crude products are obtained by concentration and water removal, and the crude products are separated and purified by column chromatography (200-mesh 300-mesh silica gel, eluent is dichloromethane: methanol-20: 1) to obtain colorless liquid intermediates 64.
830mg of intermediate 64, 775mg of 2-chloro-4-fluorobenzonitrile and 1.06g of potassium carbonate are dissolved in 30mL of DMF and stirred at room temperature for 12 hours. After the reaction, 100mL of saturated ammonium chloride solution was added to quench the reaction, the reaction was extracted three times with dichloromethane, the organic phase was washed successively with saturated aqueous ammonium chloride solution and saturated brine, and then dried over anhydrous sodium sulfate, filtered to remove sodium sulfate, and concentrated to give a crude product. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate 1:1) to yield pure intermediate 68.1H NMR(500MHz,CDCl3),δ(ppm)3.22(t,J＝5.0Hz,2H,CH2), 3.59-3.61(m,2H,CH2),3.66(s,4H,CH2),3.73-3.77(m,4H,CH2),7.23-7.25(m,1H,CH),7.39(s, 1H,CH),7.52(d,J＝5.0Hz,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)31.7,61.6,69.2,70.2,70.6,72.5,109.0,116.1,124.9,127.0,133.6,137.0,146.3；HRMS calcd for C13H16ClNO3S[M+H]+: 302.0612.
Intermediate 69.1H NMR(500MHz,CDCl3),δ(ppm)3.22(t,J＝6.5Hz,2H,CH2),3.61(t,J＝5.0Hz,2H,CH2),3.64-3.69(m,8H,CH2),3.72-3.76(m,4H,CH2),7.25(dd,J＝8.5,2.0Hz,1H,CH),7.41(d,J＝2.0Hz,1H,CH),7.52(d,J＝8.0Hz,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)31.5,61.5,69.2,70.1,70.3,70.46,70.52,72.5,108.9,116.0,124.8,126.9,133.5,136.9, 146.3；HRMS calcd for C15H20ClNO4S[M+Na]+:368.0694；found:368.0696.
An intermediate 70.1H NMR(500MHz,CDCl3),δ(ppm)3.22(t,J＝5.0Hz,2H,CH2),3.60-3.75(m, 18H,CH2),7.26(dd,J＝5.0,10.0Hz,1H,CH),7.41(d,J＝5.0Hz,1H,CH),7.53(d,J＝5.0Hz, 1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)31.5,61.6,69.4,70.1,70.4,70.52,70.58,70.6, 72.7,109.0,116.1,124.9,127.1,133.6,137.0,146.4；HRMS calcd forC17H24ClNO5S[M+Na]+: 412.0956；found:412.0951.
Intermediate 71.1H NMR(500MHz,CDCl3),δ(ppm)3.20-3.24(m,2H,CH2),3.59-3.77(m,22H, CH2),7.26(d,J＝5.0Hz,1H,CH),7.41(s,1H,CH),7.53(dd,J＝10.0,5.0Hz,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)31.6,61.5,69.2,70.1,70.35,70.41,70.44,72.5,108.8,116.0, 124.8,126.8,133.4,136.8,146.4；HRMS calcd for C19H28ClNO6S[M+Na]+:456.1218；found: 456.1267.
150mg of intermediate 68, 550mg of Diphenylphosphorylazide (DPPA) and 228mg of 1, 8-diazabicycloundecen-7-ene (DBU) were dissolved in 5mL of THF, stirred at room temperature for 6-12 hours, and after completion of intermediate 68 was detected by TLC, heating and refluxing were continued for 12 hours. After the reaction is finished, 20mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate 1:1) to yield pure intermediate 72.1H NMR(500MHz,CDCl3),δ(ppm) 3.20(t,J＝5.0Hz,2H,CH2),3.38(t,J＝5.0Hz,2H,CH2),3.64-3.68(m,4H,CH2),3.76(t,J＝5.0 Hz,2H,CH2),5.18(d,J＝10.0Hz,2H,CH2),7.20-7.25(m,1H,CH),7.33-7.40(m,1H,CH),7.40 (d,J＝5.0Hz,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)115.3,120.09,120.13,120.6,125.6,129.6,129.9,150.36,150.42；HRMS calcd for C13H15ClN4O2S[M+Na]+:349.0496；found:349.0472.
Intermediate 73.1H NMR(500MHz,CDCl3),δ(ppm)3.17-3.22(m,2H,CH2),3.34-3.40(m,2H, CH2),3.62-3.68(m,10H,CH2),3.71-3.77(m,2H,CH2),7.20-7.25(m,1H,CH),7.36-7.40(m,1H, CH),7.48-7.53(m,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)31.6,50.5,69.2,69.8,70.4, 108.8,115.9,124.8,126.8,133.4,136.8,146.4；HRMS calcd for C15H19ClN4O3S[M+Na]+: 393.0759；found:393.0756.
An intermediate body 74.1H NMR(500MHz,CDCl3),δ(ppm)2.91-2.98(m,4H,CH2),3.14-3.19(m,2H, CH2),3.32-3.36(m,2H,CH2),3.60-3.63(m,10H,CH2),3.68-3.73(m,2H,CH2),7.19-7.29(m,1H, CH),7.35-7.37(m,1H,CH),7.46-7.49(m,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)31.3, 33.7,39.9,50.2,68.8,69.5,70.1,108.3,115.6,120.1,124.0,124.5,126.4,129.0,133.1,136.3, 146.3；HRMS calcd for C17H23ClN4O4S[M+Na]+:437.1021；found:437.1008.
Intermediate 75.1H NMR(500MHz,CDCl3),δ(ppm)3.16-3.23(m,2H,CH2),3.34-3.38(m,2H, CH2),3.61-3.76(m,20H,CH2),7.08-7.12(m,1H,CH),7.37-7.38(m,1H,CH),7.48-7.52(m,1H, CH)；13C NMR(125MHz,CDCl3),δ(ppm)31.3,33.8,40.0,50.2,68.9,69.5,70.05,70.13,108.3, 115.6,120.1,123.9,124.5,126.4,129.0,133.1,136.4,146.3,151.0；HRMScalcd for C19H27ClN4O5S[M+Na]+:481.1283；found:481.1247.
652mg of intermediate 72 was dissolved in 10mL of 1M aqueous NaOH and the reaction was heated under reflux for 12 hours. After the reaction is finished, hydrochloric acid is added for neutralization reaction, crude products are obtained by concentration and water removal, and the pure intermediate 76 is obtained by column chromatography (200-mesh 300-mesh silica gel, eluent dichloromethane: methanol 20:1) separation.1H NMR(500MHz,CDCl3),δ(ppm)3.21(t,J＝5.0Hz,2H,CH2),3.39(t,J＝5.0Hz,2H,CH2),3.67-3.69(m,6H,CH2),3.76(t,J＝5.0Hz,2H,CH2),7.22 (dd,J＝5.0,10.0Hz,1H,CH),7.37(d,J＝5.0Hz,1H,CH),7.91(d,J＝5.0Hz,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)31.7,50.6,69.5,70.1,70.6,124.7,124.9,128.7,132.6,135.3, 145.0,169.7；HRMS calcd for C13H16ClN3O4S[M+Na]+:368.0442；found:368.0432.
Intermediate 77.1H NMR(500MHz,CDCl3),δ(ppm)3.17(t,J＝6.5Hz,2H,CH2),3.38(t,J＝5.0Hz,2H,CH2),3.66-3.67(m,10H,CH2),3.72(t,J＝6.5Hz,2H,CH2),7.14(d,J＝8.0Hz,1H,CH),7.29-7.30(m,1H,CH),7.79(d,J＝8.5Hz,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)31.6,50.4,69.3,69.8,70.3,70.38,70.41,70.42,124.6,126.6,128.5,132.1,134.4,143.5,169.5； HRMS calcd for C15H20ClN3O5S[M+Na]+:412.0704；found:412.0712.
Intermediate 78.1HNMR(500MHz,CDCl3),δ(ppm)3.15-3.23(m,2H,CH2),3.37-3.41(m,2H,CH2),3.68-3.76(m,16H,CH2),7.19-7.20(m,1H,CH),7.34-7.36(m,1H,CH),7.87-7.90(m,1H, CH)；13C NMR(125MHz,CDCl3),δ(ppm)31.6,50.6,69.4,69.9,70.4,70.5,113.1,124.6,125.1, 128.6,132.5,135.0,144.6,151.4,168.3；HRMS calcd for C17H24ClN3O6S[M+Na]+:456.0967； found:456.0925.
Intermediate 79.1H NMR(500MHz,CDCl3),δ(ppm)3.23-3.72(m,24H,CH2),7.34-7.90(m,3H, CH)；13C NMR(125MHz,CDCl3),δ(ppm)31.7,50.7,54.0,70.5,124.7,128.7,137.4；HRMScalcd for C19H28ClN3O7S[M+Na]+:500.1229；found:500.1207.
518mg of intermediate 76 was dissolved in 10mL of DCM, and 776mg of m-chloroperoxybenzoic acid (mCPBA) was added thereto and stirred at room temperature for 1 hour. After the reaction is finished, the solvent is concentrated and removed to obtain a crude product, the crude product is subjected to column chromatography (200-300-mesh silica gel,eluent is dichloromethane: methanol 10:1) isolated to yield pure intermediate 80.1H NMR(500MHz,CDCl3),δ(ppm)3.35(t,J ＝5.0Hz,2H,CH2),3.48-3.59(m,8H,CH2),3.91(t,J＝10.0Hz,2H,CH2),7.92(dd,J＝10.0,5.0 Hz,1H,CH),8.06(d,J＝2.0Hz,1H,CH),8.11(d,J＝10.0Hz,1H,CH)；13C NMR(125MHz, CDCl3),δ(ppm)50.5,56.4,64.5,70.0,70.2,70.5,126.2,130.9,132.5,133.5,135.0,144.5,168.3；HRMS calcd for C13H16ClN3O6S[M+Na]+:400.0341；found:400.0318.
Intermediate 81.1H NMR(500MHz,CDCl3),δ(ppm)3.58-3.42(m,4H,CH2),3.50(br,4H,CH2), 3.57-3.62(m,6H,CH2),3.82-3.84(m,2H,CH2),7.64-7.65(m,1H,CH),7.79(br,2H,CH)；13C NMR(125MHz,CDCl3),δ(ppm)50.5,55.9,64.1,69.7,70.0,70.2,70.3,126.0,129.5,130.6, 131.6,132.5,141.3；HRMS calcd for C15H20ClN3O7S[M+Na]+:444.0603；found:444.0598.
An intermediate 82.1H NMR(500MHz,CDCl3),δ(ppm)3.41(t,J＝5.0Hz,2H,CH2),3.46-3.69(m, 16H,CH2),3.89(t,J＝5.0Hz,2H,CH2),7.90(dd,J＝10.0,10.0Hz,1H,CH),8.04-8.07(m,2H, CH)；13C NMR(125MHz,CDCl3),δ(ppm)50.6,56.4,64.5,69.9,70.1,70.4,70.5,70.6,126.3, 130.8,132.3,134.7,144.2,167.2；HRMS calcd for C17H24ClN3O8S[M+Na]+:488.0865；found: 488.0855.
And (3) an intermediate 83.1H NMR(500MHz,CDCl3),δ(ppm)3.40-3.69(m,22H,CH2),3.88(t,J＝5.0Hz,2H,CH2),7.88(d,J＝10.0Hz,1H,CH),8.02-8.05(m,2H,CH)；13C NMR(125MHz,CDCl3), δ(ppm)50.5,56.3,64.4,69.8,70.0,70.2,70.28,70.32,70.36,70.4,126.2,130.5,132.0,134.3, 134.7,143.7,166.5；HRMS calcd for C19H28ClN3O9S[M+Na]+:532.1327.
To a solution of 351mg of 2- (2-chloro-5-nitrophenyl) pyridine in 10mL of ethanol was added hydrochloric acid to adjust the pH to <3, 1.35g of stannous chloride dihydrate was added, and the mixture was heated to reflux and stirred for 6 hours. Cooling to 0 ℃ after the reaction is finished, adding NaOH solution to adjust the pH value to be more than 12, filtering with diatomite to remove precipitate, concentrating to remove ethanol, extracting with ethyl acetate for 3 times, sequentially washing an organic phase with saturated ammonium chloride aqueous solution and saturated salt water, then drying with anhydrous sodium sulfate, filtering to remove sodium sulfate, and concentrating to obtain a crude product. The crude product was isolated by column chromatography (200-mesh 300-mesh silica gel, eluent n-hexane: ethyl acetate 1:1) to yield pure intermediate 84.
83mg of 80 and 117mg of HATU were dissolved in 5ml of EDCM, and the mixture was stirred at room temperature for 0.5 hour. To this solution was added 40mg of 84 and 71mg of DIPEA in 3mL DCM and stirred at room temperature for 12 hours. After the reaction is finished, 20mL of saturated ammonium chloride solution is added to quench the reaction, an organic phase is separated, a water phase is extracted for three times by using dichloromethane, the organic phase is merged, the saturated ammonium chloride aqueous solution and the saturated common salt water are sequentially used for washing, then, anhydrous sodium sulfate is used for drying, sodium sulfate is removed by filtration, and a crude product is obtained by concentration. The crude product is separated by column chromatography (200-mesh silica gel 300 meshes, eluent is n-hexane: ethyl acetate: 1) to obtain a pure intermediate TC 1306.1HNMR(500MHz,CDCl3),δ(ppm)3.16-3.21(m,4H,CH2),3.33(t,J＝5.0Hz,2H, CH2),3.42(t,J＝5.0Hz,2H,CH2),3.47-3.52(m,4H,CH2),3.57(t,J＝5.0Hz,2H,CH2), 3.68-3.74(m,4H,CH2),3.86(t,J＝5.0Hz,2H,CH2),7.31-7.34(m,1H,CH),7.48(d,J＝10.0Hz, 1H,CH),7.70-7.95(m,6H,CH),7.59(d,J＝10.0Hz,1H,CH),8.95(s,1H,CH)；13C NMR(125 MHz,CDCl3),δ(ppm).50.6,55.8,56.5,64.6,70.1,70.3,70.5,123.1,130.0；HRMS calcd forC25H23Cl2N5O5S[M+Na]+:586.0689；found:586.0722.
TC1156。1H NMR(500MHz,CDCl3),δ(ppm)3.46(t,J＝5.0Hz,2H,CH2),3.52(t,J＝5.5 Hz,2H,CH2),3.58(br,4H,CH2),3.62-3.66(m,6H,CH2),3.92(t,J＝5.5Hz,2H,CH2),7.37-7.41 (m,1H,CH),7.50(d,J＝9.0Hz,1H,CH),7.70-7.71(m,1H,CH),7.75-7.76(m,2H,CH), 7.85-7.88(m,2H,CH),7.92-7.94(m,1H,CH),8.03(d,J＝1.5Hz,1H,CH),8.62-8.63(m,1H, CH)；13C NMR(125MHz,CDCl3),δ(ppm).50.3,55.8,63.9,69.3,69.6,69.82,69.84,70.0,121.6, 122.6,122.8,125.1,126.4,127.4,129.3,129.4,130.3,131.9,136.6,138.6,140.8,141.6,148.5, 155.8,164.2；HRMS calcd for C26H27Cl2N5O6S[M+H]+:608.1132；found:608.1126.
TC1307。1H NMR(500MHz,CDCl3),δ(ppm)3.34-3.66(m,18H,CH2),3.82-3.85(m,2H,CH2),7.24-7.34(m,2H,CH),7.48(dd,J＝10.0,10.0Hz,1H,CH),7.61-7.97(m,6H,CH),8.54(d, J＝5.0Hz,1H,CH)；13C NMR(125MHz,CDCl3),δ(ppm).50.6,56.3,56.4,64.3,64.4,69.8,69.9, 70.0,70.1,70.4,70.5,121.6,122.8,122.9,125.1,129.7,130.7,136.3；HRMScalcd for C229H31Cl2N5O7S[M+Na]+:674.1213；found:674.1216.
TC820。1H NMR(600MHz,CDCl3),δ(ppm)2.80(br,2H,CH2),3.35(t,J＝5.4Hz,2H,CH2),3.40(t,J＝5.4Hz,2H,CH2),3.44-3.49(m,4H,CH2),3.53-3.54(m,2H,CH2),3.58-3.62(m, 10H,CH2),3.82(t,J＝6.0Hz,2H,CH2),7.30-7.32(m,1H,CH),7.46(d,J＝9.0Hz,1H,CH), 7.66-7.71(m,2H,CH),7.77-7.84(m,3H,CH),7.90-7.91(m,2H,CH),8.52(br,1H,CH),9.71(s, 1H,CH)；13C NMR(150MHz,CDCl3),δ(ppm).50.5,56.4,64.4,69.8,70.0,70.29,70.34,70.36, 70.43,70.47,121.8,122.9,123.0,125.4,126.7,127.3,129.6,129.7,130.7,131.8,136.96,136.99, 138.2,140.3,142.3,148.5,155.5,163.9；HRMS calcd forC30H35Cl2N5O8S[M+Na]+:718.1481； found:718.1423.
Example 2
The general synthetic approach to the dual head ligand for the smoothing receptor is described below:
two intermediate molecules, each 0.1mmol, were dissolved in 3 methanol, and 0.4mL of 1M aqueous copper sulfate solution and 0.4mL of 1M aqueous sodium ascorbate solution were added and stirred at room temperature for 1 hour. After the reaction is finished, the double-head molecule is obtained by concentration, column chromatography (200-300 mesh silica gel, eluent is dichloromethane: methanol: 10:1 to 5:1, etc.) separation and purification.
The molecular numbers and reaction yields of the two fragments corresponding to each of the double-headed ligands are shown in Table 1:
TABLE 1
Figure BDA0001798453550000631
Figure BDA0001798453550000641
And carrying out structural characterization on each ligand, which comprises the following specific steps:
Figure BDA0001798453550000642
TC802:1H NMR(800MHz,CDCl3),(ppm)0.83(s,3H,CH3),0.87-0.97(m,1H,CH2),0.98(s, 3H,CH3),1.02-1.22(m,4H,CH2and CH),1.23(s,3H,CH3),1.25-1.74(m,20H,CH2and CH), 1.80-1.82(m,2H,CH2),1.93-1.96(m,1H,CH2),2.04-2.06(m,1H,CH2),2.20-2.28(m,2H,CH2), 3.42-3.50(m,3H,CH2and CH),4.46-4.48(m,4H,CH2),4.55(s,2H,CH2),4.77-4.78(m,1H,CH), 5.31-5.32(m,1H,CH),6.99-7.00(m,1H,CH),7.21-7.27(m,1H,CH),7.40-7.51(m,6H,CH), 7.75-7.87(m,2H,CH)；13C NMR(200MHz,CDCl3),13.5,19.3,20.8,22.3,23.7,24.0,25.9, 26.2,29.4,29.9,31.2,31.5,31.7,36.4,37.2,40.0,42.1,42.5,43.8,47.9,49.9,56.8,57.5,63.9,70.6, 71.5,75.0,119.2,121.3,122.7,123.8,125.6,126.7,128.2,129.3,137.0,140.8,145.5,163.7； HRMS calcd for C60H79ClN6O5S[M+H]+:1031.5594；found:1031.5553.
Figure BDA0001798453550000651
TC803:1H NMR(800MHz,CDCl3),(ppm)0.84(s,3H,CH3),0.87-0.98(m,1H,CH2),0.99(s, 3H,CH3),1.02-1.19(m,4H,CH2and CH),1.24(s,3H,CH3),1.25-1.75(m,20H,CH2and CH), 1.80-1.85(m,2H,CH2),1.94-1.97(m,1H,CH2),2.04-2.07(m,1H,CH2),2.20-2.28(m,2H,CH2), 3.46-3.50(m,3H,CH2and CH),3.83-3.84(m,2H,CH2),3.93-3.94(m,2H,CH2),4.50-4.51(m, 2H,CH2),4.55-4.57(s,4H,CH2),4.82(br,1H,CH),5.32-5.33(m,1H,CH),6.96-7.24(m,3H, CH),7.45-7.52(m,5H,CH),7.68-7.86(m,3H,CH),8.17(br,1H,CH)；13C NMR(200MHz, CDCl3),13.5,19.3,20.8,22.3,23.7,24.1,26.0,26.3,29.5,30.0,31.2,31.5,31.7,36.4,37.2, 40.0,42.2,42.5,43.8,50.0,50.2,56.8,57.5,64.1,64.9,69.5,69.8,70.6,71.5,75.0,108.6,119.0, 121.4,122.7,123.6,125.4,126.5,127.4,129.2,137.1,140.8,145.2,147.1,164.1；HRMS calcd for C62H83ClN6O6S[M+2H]2+:538.2964；found:538.2955.
Figure BDA0001798453550000652
TC804:1H NMR(800MHz,CDCl3),(ppm)0.85(s,3H,CH3),0.87-0.98(m,1H,CH2),1.00(s, 3H,CH3),1.04-1.21(m,4H,CH2and CH),1.25(s,3H,CH3),1.26-1.75(m,20H,CH2and CH), 1.82-1.84(m,2H,CH2),1.95-2.02(m,1H,CH2),2.07-2.08(m,1H,CH2),2.20-2.29(m,2H,CH2), 3.42-3.52(m,3H,CH2and CH),3.56-3.70(m,8H,CH2),3.85-3.87(m,4H,CH2),4.51-4.53(m, 4H,CH2),4.66(s,2H,CH2),4.82(br,1H,CH),5.33-5.34(m,1H,CH),7.01-7.26(m,2H,CH), 7.45-7.50(m,4H,CH),7.70-7.87(m,3H,CH),8.17(br,1H,CH)；13CNMR(200MHz,CDCl3), 13.6,19.4,20.9,22.3,23.7,24.2,26.0,26.4,29.6,30.0,31.3,31.6,31.7,36.4,37.2,40.1,42.2, 42.6,43.9,50.0,50.2,56.8,57.6,64.5,65.1,69.5,69.6,69.8,70.0,70.46,70.51,70.57,70.58,71.4, 71.6,75.1,108.7,119.0,121.5,122.7,123.8,125.4,126.5,127.4,129.2,137.2,140.8,144.9,147.1, 164.1；HRMS calcdfor C64H87ClN6O7S[M+2H]2+:560.3096；found:560.3088.
Figure BDA0001798453550000661
TC593:1H NMR(500MHz,CDCl3),(ppm)0.86(s,3H,CH3),0.88-0.99(m,1H,CH2),1.01(s, 3H,CH3),1.02-1.25(m,4H,CH2and CH),1.26(s,3H,CH3),1.27-1.78(m,20H,CH2and CH), 1.82-1.86(m,2H,CH2),1.95-2.00(m,1H,CH2),2.07-2.11(m,1H,CH2),2.20-2.32(m,2H,CH2), 3.46-3.51(m,3H,CH2and CH),3.59-3.74(m,8H,CH2),3.84-3.90(m,4H,CH2),4.50-4.54(m, 4H,CH2),4.60(s,2H,CH2),4.82(br,1H,CH),5.31-5.32(m,1H,CH),6.84-7.15(m,3H,CH), 7.45-7.50(m,5H,CH),7.67-7.88(m,3H,CH),8.17(br,1H,CH)；13CNMR(125MHz,CDCl3), 13.4,19.2,20.7,22.2,23.6,24.0,26.0,26.2,29.4,30.0,31.1,31.4,31.6,36.3,37.1,39.9,42.2, 42.4,43.8,44.9,49.8,50.0,53.4,56.7,57.4,59.1,64.0,65.1,69.3,69.6,70.33,70.35,70.45,70.50, 70.56,70.59,71.3,74.9,108.6,115.4,118.9,121.3,122.4,122.6,123.5,125.2,125.4,126.4,127.3, 129.1,137.0,140.8,145.0,147.0,163.6,164.1；HRMS calcd for C66H91ClN6O8S[M+2H]2+: 582.3227；found:582.3217.
Figure BDA0001798453550000662
TC594:1H NMR(500MHz,CDCl3),(ppm)0.86(s,3H,CH3),0.88-0.99(m,1H,CH2),1.01(s, 3H,CH3),1.02-1.25(m,4H,CH2and CH),1.26(s,3H,CH3),1.27-1.78(m,20H,CH2and CH), 1.82-1.86(m,2H,CH2),1.95-2.00(m,1H,CH2),2.07-2.11(m,1H,CH2),2.20-2.32(m,2H,CH2), 3.46-3.51(m,3H,CH2and CH),3.59-3.74(m,8H,CH2),3.84-3.90(m,4H,CH2),4.50-4.54(m, 4H,CH2),4.60(s,2H,CH2),4.82(br,1H,CH),5.31-5.32(m,1H,CH),6.84-7.15(m,3H,CH), 7.45-7.50(m,5H,CH),7.67-7.88(m,3H,CH),8.17(br,1H,CH)；13CNMR(125MHz,CDCl3), 13.4,19.2,20.7,22.2,23.6,24.0,26.0,26.2,29.4,30.0,31.1,31.4,31.6,36.3,37.1,39.9,42.2, 42.4,43.8,44.9,49.8,50.0,53.4,56.7,57.4,59.1,64.0,65.1,69.3,69.6,70.33,70.35,70.45,70.50, 70.56,70.59,71.3,74.9,108.6,115.4,118.9,121.3,122.4,122.6,123.5,125.2,125.4,126.4,127.3, 129.1,137.0,140.8,145.0,147.0,163.6,164.1；HRMS calcd for C68H95ClN6O9S[M+2H]2+: 604.3358；found:604.3347.
Figure BDA0001798453550000671
TC595:1H NMR(500MHz,CDCl3),(ppm)0.86(s,3H,CH3),0.88-0.99(m,1H,CH2),1.01(s, 3H,CH3),1.02-1.25(m,4H,CH2and CH),1.26(s,3H,CH3),1.27-1.78(m,20H,CH2and CH), 1.82-1.86(m,2H,CH2),1.95-2.00(m,1H,CH2),2.07-2.11(m,1H,CH2),2.20-2.32(m,2H,CH2), 3.46-3.51(m,3H,CH2and CH),3.59-3.74(m,8H,CH2),3.84-3.90(m,4H,CH2),4.50-4.54(m, 4H,CH2),4.60(s,2H,CH2),4.82(br,1H,CH),5.31-5.32(m,1H,CH),6.84-7.15(m,3H,CH), 7.45-7.50(m,5H,CH),7.67-7.88(m,3H,CH),8.17(br,1H,CH)；13CNMR(125MHz,CDCl3), 13.4,19.2,20.7,22.2,23.6,24.0,26.0,26.2,29.4,30.0,31.1,31.4,31.6,36.3,37.1,39.9,42.2, 42.4,43.8,44.9,49.8,50.0,53.4,56.7,57.4,59.1,64.0,65.1,69.3,69.6,70.33,70.35,70.45,70.50, 70.56,70.59,71.3,74.9,108.6,115.4,118.9,121.3,122.4,122.6,123.5,125.2,125.4,126.4,127.3, 129.1,137.0,140.8,145.0,147.0,163.6,164.1；HRMS calcd for C70H99ClN6O10S[M+2H]2+: 626.3489；found:626.3477.
Figure BDA0001798453550000672
TC596:1H NMR(500MHz,CDCl3),(ppm)0.86(s,3H,CH3),0.88-0.99(m,1H,CH2),1.01(s, 3H,CH3),1.02-1.25(m,4H,CH2and CH),1.26(s,3H,CH3),1.27-1.78(m,20H,CH2and CH), 1.82-1.86(m,2H,CH2),1.95-2.00(m,1H,CH2),2.07-2.11(m,1H,CH2),2.20-2.32(m,2H,CH2), 3.46-3.51(m,3H,CH2and CH),3.59-3.74(m,8H,CH2),3.84-3.90(m,4H,CH2),4.50-4.54(m, 4H,CH2),4.60(s,2H,CH2),4.82(br,1H,CH),5.31-5.32(m,1H,CH),6.84-7.15(m,3H,CH), 7.45-7.50(m,5H,CH),7.67-7.88(m,3H,CH),8.17(br,1H,CH)；13CNMR(125MHz,CDCl3), 13.4,19.2,20.7,22.2,23.6,24.0,26.0,26.2,29.4,30.0,31.1,31.4,31.6,36.3,37.1,39.9,42.2, 42.4,43.8,44.9,49.8,50.0,53.4,56.7,57.4,59.1,64.0,65.1,69.3,69.6,70.33,70.35,70.45,70.50, 70.56,70.59,71.3,74.9,108.6,115.4,118.9,121.3,122.4,122.6,123.5,125.2,125.4,126.4,127.3, 129.1,137.0,140.8,145.0,147.0,163.6,164.1；HRMS calcd for C72H103ClN6O11S[M+2H]2+: 648.3620；found:648.3609.
Figure BDA0001798453550000681
TC589:1H NMR(500MHz,CDCl3),(ppm)0.86(s,3H,CH3),0.88-0.99(m,1H,CH2),1.01(s, 3H,CH3),1.02-1.25(m,4H,CH2and CH),1.26(s,3H,CH3),1.27-1.78(m,20H,CH2and CH), 1.82-1.86(m,2H,CH2),1.95-2.00(m,1H,CH2),2.07-2.11(m,1H,CH2),2.20-2.32(m,2H,CH2), 3.46-3.51(m,3H,CH2and CH),3.59-3.74(m,8H,CH2),3.84-3.90(m,4H,CH2),4.50-4.54(m, 4H,CH2),4.60(s,2H,CH2),4.82(br,1H,CH),5.31-5.32(m,1H,CH),6.84-7.15(m,3H,CH), 7.45-7.50(m,5H,CH),7.67-7.88(m,3H,CH),8.17(br,1H,CH)；13CNMR(125MHz,CDCl3), 13.4,19.2,20.7,22.2,23.6,24.0,26.0,26.2,29.4,30.0,31.1,31.4,31.6,36.3,37.1,39.9,42.2, 42.4,43.8,44.9,49.8,50.0,53.4,56.7,57.4,59.1,64.0,65.1,69.3,69.6,70.33,70.35,70.45,70.50, 70.56,70.59,71.3,74.9,108.6,115.4,118.9,121.3,122.4,122.6,123.5,125.2,125.4,126.4,127.3, 129.1,137.0,140.8,145.0,147.0,163.6,164.1；HRMS calcd for C74H107ClN6O12S[M+2H]2+: 670.3751；found:670.3737.
Figure BDA0001798453550000682
TC597:1H NMR(500MHz,CDCl3),(ppm)0.86(s,3H,CH3),0.88-0.99(m,1H,CH2),1.01(s, 3H,CH3),1.02-1.25(m,4H,CH2and CH),1.26(s,3H,CH3),1.27-1.78(m,20H,CH2and CH), 1.82-1.86(m,2H,CH2),1.95-2.00(m,1H,CH2),2.07-2.11(m,1H,CH2),2.20-2.32(m,2H,CH2), 3.46-3.51(m,3H,CH2and CH),3.59-3.74(m,8H,CH2),3.84-3.90(m,4H,CH2),4.50-4.54(m, 4H,CH2),4.60(s,2H,CH2),4.82(br,1H,CH),5.31-5.32(m,1H,CH),6.84-7.15(m,3H,CH), 7.45-7.50(m,5H,CH),7.67-7.88(m,3H,CH),8.17(br,1H,CH)；13CNMR(125MHz,CDCl3), 13.4,19.2,20.7,22.2,23.6,24.0,26.0,26.2,29.4,30.0,31.1,31.4,31.6,36.3,37.1,39.9,42.2, 42.4,43.8,44.9,49.8,50.0,53.4,56.7,57.4,59.1,64.0,65.1,69.3,69.6,70.33,70.35,70.45,70.50, 70.56,70.59,71.3,74.9,108.6,115.4,118.9,121.3,122.4,122.6,123.5,125.2,125.4,126.4,127.3, 129.1,137.0,140.8,145.0,147.0,163.6,164.1；HRMS calcd for C76H111ClN6O13S[M+2H]2+: 692.3882；found:692.3866.
Figure BDA0001798453550000691
TC598:1H NMR(500MHz,CDCl3),(ppm)0.86(s,3H,CH3),0.88-0.99(m,1H,CH2),1.01(s, 3H,CH3),1.02-1.25(m,4H,CH2and CH),1.26(s,3H,CH3),1.27-1.78(m,20H,CH2and CH), 1.82-1.86(m,2H,CH2),1.95-2.00(m,1H,CH2),2.07-2.11(m,1H,CH2),2.20-2.32(m,2H,CH2), 3.46-3.51(m,3H,CH2and CH),3.59-3.74(m,8H,CH2),3.84-3.90(m,4H,CH2),4.50-4.54(m, 4H,CH2),4.60(s,2H,CH2),4.82(br,1H,CH),5.31-5.32(m,1H,CH),6.84-7.15(m,3H,CH), 7.45-7.50(m,5H,CH),7.67-7.88(m,3H,CH),8.17(br,1H,CH)；13CNMR(125MHz,CDCl3), 13.4,19.2,20.7,22.2,23.6,24.0,26.0,26.2,29.4,30.0,31.1,31.4,31.6,36.3,37.1,39.9,42.2, 42.4,43.8,44.9,49.8,50.0,53.4,56.7,57.4,59.1,64.0,65.1,69.3,69.6,70.33,70.35,70.45,70.50, 70.56,70.59,71.3,74.9,108.6,115.4,118.9,121.3,122.4,122.6,123.5,125.2,125.4,126.4,127.3, 129.1,137.0,140.8,145.0,147.0,163.6,164.1；HRMS calcd for C78H115ClN6O14S[M+2H]2+: 714.4013；found:714.4000.
Figure BDA0001798453550000692
TC805:1H NMR(800MHz,CDCl3),(ppm)0.85(s,3H,CH3),0.87-0.98(m,1H,CH2),1.00(s, 3H,CH3),1.04-1.21(m,4H,CH2and CH),1.25(s,3H,CH3),1.26-1.75(m,20H,CH2and CH), 1.82-1.84(m,2H,CH2),1.95-2.02(m,1H,CH2),2.07-2.08(m,1H,CH2),2.20-2.29(m,2H,CH2), 3.42-3.52(m,3H,CH2and CH),3.56-3.70(m,8H,CH2),3.85-3.87(m,4H,CH2),4.51-4.53(m, 4H,CH2),4.66(s,2H,CH2),4.82(br,1H,CH),5.33-5.34(m,1H,CH),7.01-7.26(m,3H,CH), 7.45-7.50(m,5H,CH),7.70-7.87(m,3H,CH),8.17(br,1H,CH)；13CNMR(200MHz,CDCl3), 13.6,19.4,20.9,22.3,23.7,24.2,26.0,26.4,29.6,30.0,31.3,31.6,31.7,36.4,37.2,40.1,42.2, 42.6,43.9,50.0,50.2,56.8,57.6,64.5,65.1,69.5,69.6,69.8,70.0,70.46,70.51,70.57,70.58,71.4, 71.6,75.1,108.7,119.0,121.5,122.7,123.8,125.4,126.5,127.4,129.2,137.2,140.8,144.9,147.1, 164.1；HRMS calcdfor C68H95ClN6O9S[M+H]+:1207.6643；found:1207.6626.
Figure BDA0001798453550000701
TC806:1H NMR(800MHz,CDCl3),(ppm)0.85(s,3H,CH3),0.87-0.98(m,1H,CH2),1.00(s, 3H,CH3),1.04-1.21(m,4H,CH2and CH),1.25(s,3H,CH3),1.26-1.75(m,20H,CH2and CH), 1.82-1.84(m,2H,CH2),1.95-2.02(m,1H,CH2),2.07-2.08(m,1H,CH2),2.20-2.29(m,2H,CH2), 3.42-3.52(m,3H,CH2and CH),3.56-3.70(m,8H,CH2),3.85-3.87(m,4H,CH2),4.51-4.53(m, 4H,CH2),4.66(s,2H,CH2),4.82(br,1H,CH),5.33-5.34(m,1H,CH),7.01-7.26(m,2H,CH), 7.45-7.50(m,4H,CH),7.70-7.87(m,3H,CH),8.17(br,1H,CH)；13CNMR(200MHz,CDCl3), 13.6,19.4,20.9,22.3,23.7,24.2,26.0,26.4,29.6,30.0,31.3,31.6,31.7,36.4,37.2,40.1,42.2, 42.6,43.9,50.0,50.2,56.8,57.6,64.5,65.1,69.5,69.6,69.8,70.0,70.46,70.51,70.57,70.58,71.4, 71.6,75.1,108.7,119.0,121.5,122.7,123.8,125.4,126.5,127.4,129.2,137.2,140.8,144.9,147.1, 164.1；HRMS calcdfor C68H95ClN6O9S[M+H]+:1207.6643；found:1207.6628.
Figure BDA0001798453550000711
TC808:1H NMR(800MHz,CDCl3),(ppm)0.65 and 0.70(s,3H,CH3),0.87-0.94(m,2H,CH2), 0.96-1.63(m,30H,CH3,CH2and CH),1.73-2.02(m,10H,CH2),2.19-2.77(m,10H,CH2and CH), 3.40-3.52(m,4H,CH2),3.55-3.73(m,12H,CH2),3.81-3.89(m,5H,CH2andCH),4.49-4.53(m, 4H,CH2),4.65 and 4.67(s,2H,CH2),4.82(br,1H,CH2),5.31-5.33(m,1H,CH),6.85-7.14(m,2H, CH),7.44-7.52(m,5H,CH),7.66-7.88(m,4H,CH),8.17(br,1H,CH)；13C NMR(200MHz, CDCl3),50.2,61.6,64.3,65.2,69.4,69.8,70.46,70.49,70.55,70.63,71.9,108.7,119.0, 122.7,123.9,125.4,126.5,127.5,129.2,137.2,147.1,164.2；HRMS calcd for C67H94ClN7O8S [M+2H]2+:596.8359；found:596.8366.
Figure BDA0001798453550000712
TC815:1H NMR(800MHz,CDCl3),(ppm)0.67(s,3H,CH3),0.90(d,J＝6.4Hz,3H,CH3), 0.91-0.98(m,2H,CH2),0.99(s,3H,CH3),1.01-1.58(m,30H,CH2and CH),1.79-1.86(m,5H, CH2),2.04-2.29(m,2H,CH2),3.43(t,J＝7.2Hz,2H,CH2),3.48-3.52(m,1H,CH2),3.57-3.62(m, 7H,CH2),3.65-3.68(m,4H,CH2),3.72-3.74(m,2H,CH2),3.84(t,J＝4.8Hz,2H,CH2),3.88(t,J ＝4.8Hz,2H,CH2),4.50-4.53(m,4H,CH2),4.67(s,2H,CH2),4.82(br,1H,CH),5.33-5.34(m, 1H,CH),6.84-7.13(m,2H,CH),7.44-7.50(m,5H,CH),7.66-7.88(m,3H,CH),8.17(br,1H,CH)；13C NMR(200MHz,CDCl3),11.8,18.7,19.5,20.0,24.2,25.9,26.1,28.2,29.6,30.0,31.6, 31.85,31.86,35.7,35.8,36.4,37.2,39.7,42.3,50.1,50.2,56.0,56.7,64.5,65.2,69.4,69.6,69.8, 69.9,70.48,70.52,70.59,70.63,71.5,71.7,108.7,119.1,121.6,122.7,123.8,125.4,126.5,127.4, 129.2,137.2,140.8,144.9,147.1,164.2；HRMS calcd for C68H95ClN6O8S[M+2H]2+:596.3383； found:596.3377.
Figure BDA0001798453550000721
TC673:1H NMR(800MHz,CDCl3),(ppm)0.84-1.04(m,12H,CH2and CH),1.17-2.02(m, 38H,CH2and CH),2.20-2.54(m,9H,CH2and CH),3.58-3.73(m,16H,CH2),3,79(br,2H,CH2), 3,87-3.88(m,2H,CH2),4.22-4.25(m,1H,CH),4.40(br,2H,CH2),4.52-4.57(m,3H,CH2and CH),5.34-5.39(m,1H,CH),6.88-7.14(m,2H,CH),7.32-7.62(m,5H,CH),7.74-7.95(m,3H, CH),8.14-8.16(m,1H,CH)；13C NMR(200MHz,CDCl3),29.7,31.3,41.5,70.3,70.5,70.7, 141.6,143.3,147.2,150.8,153.6,155.0,164.3；HRMS calcd for C72H96ClN7O11S[M+2H]2+: 651.8361；found:651.8367.
Figure BDA0001798453550000722
TC814:1H NMR(800MHz,CDCl3),(ppm)0.63(s,3H,CH3),0.90(d,J＝6.4Hz,3H,CH3), 0.92-0.98(m,1H,CH2),1.01(s,3H,CH3),1.06-1.64(m,24H,CH2and CH),1.73-1.84(m,5H, CH2),1.93-2.01(m,2H,CH2),3.40(t,J＝7.2Hz,2H,CH2),3.57-3.72(m,20H,CH2),3.84(t,J＝ 4.8Hz,2H,CH2),3.88(t,J＝4.8Hz,2H,CH2),4.50-4.52(m,4H,CH2),4.67(s,2H,CH2),4.82(br, 1H,CH),6.84-7.13(m,2H,CH),7.44-7.49(m,5H,CH),7.65-7.87(m,3H,CH),8.17(br,1H,CH)；13C NMR(200MHz,CDCl3),11.9,18.5,20.7,23.3,24.1,26.1,26.3,27.1,28.2,29.6,30.4, 31.6,31.9,34.5,35.3,35.5,35.8,36.4,40.1,40.3,42.0,42.6,50.1,56.0,56.4,64.5,69.4,69.6,69.7, 69.9,70.42,70.46,70.52,70.54,70.58,71.63,71.67,72.0,99.9,108.7,119.1,122.7,123.8,125.4, 126.5,127.4,129.2,137.1,144.8,147.1,163.6,164.2；HRMS calcd for C67H95ClN6O9S[M+2H]2+: 598.3358；found:598.3363.
Figure BDA0001798453550000731
TC829:1H NMR(800MHz,CDCl3),(ppm)0.84(s,3H,CH3),0.85-0.98(m,1H,CH2),0.99(s, 3H,CH3),1.03-1.21(m,4H,CH2and CH),1.25(s,3H,CH3),1.38-1.75(m,12H,CH2and CH), 1.81-1.83(m,2H,CH2),1.94-1.97(m,2H,CH2),2.07-2.09(m,1H,CH2),2.14-2.29(m,4H,CH2), 3.48-3.54(m,3H,CH2and CH),3.59-3.63(m,6H,CH2),3.65-3.68(m,4H,CH2),3.72-3.73(m, 2H,CH2),3.84(t,J＝4.8Hz,2H,CH2),3.88(t,J＝4.8Hz,2H,CH2),4.50-4.53(m,4H,CH2),4.66 (s,2H,CH2),4.81(br,1H,CH),5.32-5.33(m,1H,CH),6.85-7.13(m,3H,CH),7.44-7.50(m,5H, CH),7.65-7.88(m,4H,CH),8.17(br,1H,CH)；13C NMR(200MHz,CDCl3),13.5,13.6, 19.3,20.0,20.9,22.4,23.7,25.6,31.3,31.6,31.7,36.4,37.2,40.1,41.9,42.2,42.6,50.0,50.2,56.8, 58.6,64.5,65.2,69.4,69.5,69.8,69.9,70.1,70.47,70.51,70.58,70.63,71.6,74.7,76.9,81.6, 108.7,119.2,121.4,122.7,123.8,126.6,127.4,137.2,140.8,144.8,147.1,163.7,164.3；HRMS calcd forC68H91ClN6O9S[M+2H]2+:602.3201；found:602.3198.
Figure BDA0001798453550000732
TC813:1H NMR(800MHz,CDCl3),(ppm)0.85(s,3H,CH3),0.87-0.99(m,1H,CH2),1.00(s, 3H,CH3),1.04-1.21(m,4H,CH2and CH),1.25(s,3H,CH3),1.26-1.75(m,20H,CH2and CH), 1.82-1.87(m,4H,CH2),1.95-2.02(m,4H,CH2),2.06-2.09(m,1H,CH2),2.20-2.30(m,2H,CH2), 2.38-2.48(m,4H,CH2),3.42-3.52(m,3H,CH2and CH),3.58-3.68(m,12H,CH2),3.72-3.74(m, 2H,CH2),3.86-3.88(m,4H,CH2),4.51-4.53(m,4H,CH2),4.68(s,2H,CH2),4.81(br,1H,CH), 5.33-5.34(m,1H,CH),6.83(br,1H,CH),7.36-7.62(m,6H,CH),7.75-7.87(m,3H,CH), 8.26-8.36(m,1H,CH)；HRMS calcd for C68H95ClN6O9S[M+2H]2+:604.3358；found:604.3327.
Figure BDA0001798453550000741
TC807:1H NMR(800MHz,CDCl3),(ppm)0.86(s,3H,CH3),0.87-0.99(m,2H,CH2),1.00(s, 3H,CH3),1.05-1.22(m,3H,CH2and CH),1.26(s,3H,CH3),1.26-1.77(m,20H,CH2and CH), 1.83-1.85(m,2H,CH2),1.95-2.02(m,4H,CH2),2.07-2.09(m,2H,CH2),2.16-2.30(m,4H,CH2), 2.75 and 3.10(s,3H,CH3),2.93-2.97(m,1H,CH),3.38-3.45(m,3H,CH2and CH),3.50-3.54(m, 2H,CH2),3.58-3.73(m,10H,CH2),3.87-3.89(m,4H,CH2),4.01and 4.05(s,3H,CH3),4.17-4.24 (m,3H,CH2),4.52-4.53(m,2H,CH2),4.68 and 4.69(s,2H,CH2),4.90-4.94(m,1H,CH), 5.34-5.35(m,1H,CH),6.58-6.61(m,1H,CH),7.12-7.13(m,1H,CH),7.23-7.26(m,1H,CH), 7.65-7.66(m,1H,CH),7.74(s,1H,CH),7.83(t,J＝8.0Hz,1H,CH),7.88(t,J＝8.0Hz,1H,CH), 8.05(q,J＝8.0Hz,1H,CH),8.12(d,J＝8.0Hz,1H,CH)；13C NMR(200MHz,CDCl3), 13.6,19.4,20.9,22.3,23.7,24.2,26.0,26.4,29.3,29.5,30.1,31.3,31.6,31.7,36.5,37.2,40.1,42.2, 42.6,43.9,50.0,50.2,51.2,56.9,57.6,64.6,67.9,69.44,69.48,69.7,70.0,70.51,70.58,70.9,71.5, 71.7,75.2,121.5；HRMS calcd for C66H92F3N9O9[M+2H]2+:606.8558；found:606.8561.
Figure BDA0001798453550000742
TC809:1H NMR(800MHz,CDCl3),(ppm)0.69 and 0.72(s,3H,CH3),0.94-0.95(m,1H,CH2), 1.00(s,3H,CH3),1.03-1.63(m,26H,CH2and CH),1.76-1.86(m,4H,CH2),1.96-2.01(m,4H, CH2),2.20-2.29(m,4H,CH2),2.76 and 3.10(s,3H,CH3),2.92-2.98(m,1H,CH),3.38-3.52(m, 5H,CH2and CH),3.58-3.73(m,14H,CH2),3.87-3.89(m,4H,CH2),4.02and 4.06(s,3H,CH3), 4.18-4.21(m,3H,CH2),4.52-4.53(m,2H,CH2),4.67 and 4.68(s,2H,CH2),4.91-4.94(m,1H, CH),5.33-5.34(m,1H,CH),6.58-6.61(m,1H,CH),7.12-7.13(m,1H,CH),7.24-7.28(m,1H, CH),7.65-7.66(m,1H,CH),7.74-7.76(m,1H,CH),7.83(t,J＝8.0Hz,1H,CH),7.87(t,J＝8.0 Hz,1H,CH),8.03-8.06(m,1H,CH),8.12(d,J＝8.0Hz,1H,CH)；13C NMR(200MHz,CDCl3), 12.1,12.4,,19.4,20.8,23.8,23.9,24.1,29.2,29.5,31.5,31.6,31.7,36.4,37.2,38.2,39.2, 42.0,42.2,49.87,49.94,50.2,51.2,56.5,64.5,67.9,69.41,69.44,69.6,69.9,70.48,70.50,70.55, 70.8,71.1,71.3,71.6,109.1,118.1,121.4,123.7,124.7,126.2,131.4,131.9,138.1；HRMS calcd for C65H91F3N10O8[M+2H]2+:599.3559；found:599.3556.
Figure BDA0001798453550000751
TC836:1H NMR(800MHz,CDCl3),(ppm)0.67(s,3H,CH3),0.87-0.88(m,1H,CH),0.89(d, J＝4.8Hz,3H,CH3),0.91-0.99(m,5H,CH2and CH),1.00(s,3H,CH3),1.01-1.59(m,28H,CH2and CH),1.75-1.85(m,5H,CH2),1.95-2.01(m,4H,CH2),2.18-2.30(m,4H,CH2),2.76and 3.10 (s,3H,CH3),2.93-3.00(m,2H,CH),3.36-3.53(m,5H,CH2and CH),3.58-3.73(m,12H,CH2), 3.87-3.89(m,4H,CH2),4.01 and 4.05(s,3H,CH3),4.18-4.21(m,3H,CH2),4.52-4.54(m,2H, CH2),4.68 and 4.69(s,2H,CH2),4.90-4.94(m,1H,CH),5.33-5.34(m,1H,CH),6.58-6.59(m,1H, CH),7.12-7.13(m,1H,CH),7.24-7.28(m,1H,CH),7.65-7.66(m,1H,CH),7.75(s,1H,CH),7.83 (t,J＝8.0Hz,1H,CH),7.88(t,J＝8.0Hz,1H,CH),8.05(q,J＝8.0Hz,1H,CH),8.12(d,J＝8.0 Hz,1H,CH)；13C NMR(200MHz,CDCl3),13.6,19.4,20.9,22.3,23.7,24.2,26.0,26.4,29.3, 29.5,30.1,31.3,31.6,31.7,36.5,37.2,40.1,42.2,42.6,43.9,50.0,50.2,51.2,56.9,57.6,64.6,67.9, 69.44,69.48,69.7,70.0,70.51,70.58,70.9,71.5,71.7,75.2,121.5；HRMS calcd for C66H92F3N9O8[M+2H]2+:598.8583；found:598.8580.
Figure BDA0001798453550000761
TC838:1H NMR(800MHz,CDCl3),(ppm)0.84(s,3H,CH3),0.86-0.99(m,2H,CH2),1.00(s, 3H,CH3),1.05-1.22(m,3H,CH2and CH),1.26(s,3H,CH3),1.27-1.75(m,16H,CH2and CH), 1.82-1.85(m,3H,CH2),1.93-2.02(m,4H,CH2),2.08-2.28(m,8H,CH2),2.40-2.43(m,2H,CH2), 2.68 and 2.75(s,3H,CH3),2.99 and 3.10(s,3H,CH3),3.41-3.56(m,4H,CH2and CH),3.61-3.73 (m,16H,CH2),3.86-3.89(m,5H,CH2),3.92(s,2H,CH2),4.01and 4.05(s,3H,CH3),4.18-4.21 (m,3H,CH2),4.52-4.54(m,2H,CH2),4.68 and 4.69(s,2H,CH2),5.34-5.35(m,1H,CH), 6.55-6.60(m,1H,CH),7.11-7.14(m,1H,CH),7.20-7.27(m,1H,CH),7.64-7.67(m,1H,CH), 7.75-7.76(m,1H,CH),7.85-7.90(m,1H,CH),8.04-8.08(m,1H,CH),8.13(d,J＝8.0Hz,1H, CH),8.51-8.52(m,1H,CH)；13C NMR(200MHz,CDCl3),13.5,13.6,19.3,20.0,20.9,22.4, 23.7,29.3,31.2,31.6,31.7,36.4,37.2,37.8,41.9,42.2,42.7,50.0,50.2,56.9,58.6,64.5,67.9,69.4, 69.6,69.9,70.1,70.5,70.8,108.7,126.3,132.1,134.0,138.4；HRMS calcd for C66H88F3N9O9[M+2H]2+:604.8401；found:604.8407.
Figure BDA0001798453550000762
TC821:1H NMR(800MHz,CDCl3),(ppm)0.84(s,3H,CH3),0.86-0.98(m,1H,CH2),1.00(s, 3H,CH3),1.03-1.20(m,4H,CH2and CH),1.24(s,3H,CH3),1.26-1.82(m,22H,CH2and CH), 1.95-1.97(m,1H,CH2),2.06-2.08(m,1H,CH2),2.21-2.26(m,2H,CH2),3.43-3.58(m,8H,CH2), 3.55-3.59(m,12H,CH2),3.82-3.83(m,4H,CH2),4.52-4.58(m,3H,CH),5.33-5.34(m,1H,CH), 7.50(br,1H,CH),7.78(br,1H,CH),7.85(br,1H,CH),7.94-7.95(m,1H,CH)；13C NMR(200 MHz,CDCl3),13.6,19.4,20.9,22.3,23.7,24.2,26.0,26.3,29.5,30.0,31.2,31.5,31.7,36.4, 37.2,40.0,42.2,42.6,43.9,50.0,56.4,56.8,57.6,64.5,70.1,70.32,70.38,70.45,71.4,71.6,75.2, 121.5,126.8,140.7；HRMS calcd forC62H87Cl2N5O12S[M+2H]2+:598.7797；found:598.7799.
Figure BDA0001798453550000771
TC822:Colorless oil,isolated yield 72％.1H NMR(600MHz,CDCl3),(ppm)0.67and 0.71(s, 3H,CH3),0.86-0.94(m,2H,CH2),0.98(s,3H,CH3),1.04-1.68(m,26H,CH2andCH),1.80-2.02 (m,8H,CH2and CH),2.20-2.29(m,4H,CH2),2.85-2.96(m,2H,CH2),3.42-3.65(m,20H,CH2), 3.80-3.85(m,4H,CH2),4.49(t,J＝4.8Hz,2H,CH2),4.60(s,1H,CH),5.31-5.32(m,1H,CH), 7.29-7.32(m,1H,CH),7.47(d,J＝9.0Hz,1H,CH),7.69(d,J＝6.5Hz,1H,CH),7.76-7.80(m, 3H,CH),7.84-7.96(m,4H,CH),8.62-8.63(m,1H,CH)；13C NMR(150MHz,CDCl3),11.9, 12.6,14.1,15.4,16.2,19.34,19.38,20.7,20.8,22.6,23.6,24.3,25.7,26.8,27.2,28.7,29.3,29.7, 31.5,31.6,36.4,36.5,37.2,39.0,42.1,42.3,42.4,42.5,49.7,50.1,52.2,56.2,56.4,56.7,64.2,64.5, 69.3,69.6,69.9,70.1,70.3,70.39,70.42,70.67,70.71,71.5,121.2,121.8,122.8,123.1,124.1, 125.2,126.7,127.5,129.7,130.0,130.6,132.0,136.2,137.1,139.1,140.4,140.7；HRMS calcd forC61H86Cl2N6O11S[M+2H]2+:591.2799；found:591.2798.
Figure BDA0001798453550000772
TC823:1H NMR(800MHz,CDCl3),(ppm)0.67(s,3H,CH3),0.90(d,J＝6.4Hz,3H,CH3), 0.91-0.97(m,1H,CH2),0.99(s,3H,CH3),1.04-1.57(m,22H,CH2and CH),1.80-1.84(m,2H, CH2),1.95-2.00(m,2H,CH2),2.21-2.27(m,2H,CH2),3.44-3.60(m,20H,CH2),3.83-3.90(m,4H, CH2),4.57-4.59(m,3H,CH),5.33-5.34(m,1H,CH),7.53(br,1H,CH),7.85(br,2H,CH),7.95(br, 1H,CH),8.10(br,2H,CH)；13C NMR(200MHz,CDCl3),11.8,18.6,19.3,21.0,24.2,25.9, 26.1,28.2,29.6,29.9,31.6,31.8,35.6,35.8,36.4,37.2,39.7,42.19,42.24,50.0,56.0,56.4,56.7, 64.5,69.9,70.11,70.33,70.38,70.47,71.5,71.7,75.2,121.6,126.8,129.7,132.7,140.3,140.7, 142.5,143.6；HRMS calcd for C62H87Cl2N5O11S[M+2H]2+:590.7823；found:590.7816.
Figure BDA0001798453550000781
TC839:Colorless oil,isolated yield 45％.1H NMR(600MHz,CDCl3),(ppm)0.83(s,3H,CH3), 0.87-0.93(m,1H,CH2),0.99(s,3H,CH3),1.02-1.19(m,3H,CH2and CH),1.24(s,3H,CH3), 1.26-2.42(m,26H,CH2and CH),3.43-3.84(m,24H,CH2),4.50-4.60(m,3H,CH),5.30-5.33(m, 1H,CH),7.47(br,2H,CH),7.75-7.95(m,6H,CH)；13C NMR(150MHz,CDCl3),13.5,13.8, 19.3,20.3,20.8,22.4,23.7,25.4,31.2,31.5,31.7,36.4,37.1,40.0,41.9,42.1,42.6,49.9,56.4,56.8, 58.5,64.5,69.1,69.6,69.7,69.99,70.04,70.2,70.3,70.4,71.6,74.7,77.5,82.2,121.4,121.8, 126.8,129.7,131.9,140.4,140.7,142.5,164.0；HRMS calcd for C62H83Cl2N5O12S[M+2H]2+: 596.7641；found:596.7639.
Figure BDA0001798453550000782
TC1055:1H NMR(800MHz,CDCl3),(ppm)0.84(s,3H,CH3),0.87-0.92(m,1H,CH2),1.00(s, 3H,CH3),1.05-1.20(m,4H,CH2and CH),1.23(s,3H,CH3),1.26-2.25(m,24H,CH2and CH), 3.40-3.64(m,10H,CH2),3.73-3.84(m,4H,CH2),5.30-5.34(m,1H,CH),7.31-7.44(m,2H,CH), 7.71-7.94(m,3H,CH)；13C NMR(200MHz,CDCl3),13.6,19.4,20.9,22.4,23.7,24.1,26.0, 26.3,29.5,30.0,31.3,31.6,31.7,36.4,37.2,40.0,42.2,42.6,43.8,50.0,56.6,56.8,57.6,64.6,70.0, 70.3,71.7,75.2,121.5,140.7；HRMS calcd forC56H75Cl2N5O9S[M+2H]2+:532.7404；found: 532.7390.
Figure BDA0001798453550000783
TC1056:1H NMR(500MHz,CDCl3),(ppm)0.84(s,3H,CH3),0.87-0.92(m,1H,CH2),0.99(s, 3H,CH3),1.05-1.20(m,4H,CH2and CH),1.25(s,3H,CH3),1.26-2.25(m,24H,CH2and CH), 3.39-3.72(m,14H,CH2),3.81-3.90(m,4H,CH2),5.30-5.34(m,1H,CH),7.46-7.66(m,2H,CH), 7.82-7.96(m,3H,CH)；13C NMR(125MHz,CDCl3),13.6,19.3,20.8,22.2,23.6,24.1,25.9, 26.2,29.4,30.0,31.2,31.5,31.6,36.4,37.1,40.0,42.1,42.5,43.8,49.9,56.4,56.8,57.5,64.4,70.0, 70.27,70.35,70.43,71.4,71.5,75.1,109.9,121.4,126.8,140.7；HRMS calcd for C58H79Cl2N5O10S [M+2H]2+:554.7535；found:554.7539.
Figure BDA0001798453550000791
TC1057:1H NMR(800MHz,CDCl3),(ppm)0.84(s,3H,CH3),0.87-0.92(m,1H,CH2),1.00(s, 3H,CH3),1.04-1.21(m,3H,CH2and CH),1.25(s,3H,CH3),1.31-1.84(m,16H,CH2and CH), 1.96-2.08(m,2H,CH2),2.20-2.29(m,2H,CH2),3.36-3.66(m,20H,CH2),3.82-3.87(m,4H,CH2), 5.32-5.34(m,1H,CH),7.33-7.47(m,2H,CH),7.63-7.96(m,6H,CH)；13CNMR(200MHz, CDCl3),13.6,19.3,20.9,22.3,23.7,24.1,26.0,26.3,29.4,29.5,30.0,31.2,31.6,31.7,36.4, 37.2,40.0,42.2,42.6,43.8,50.0,56.4,56.8,57.6,64.4,69.1,69.3,69.66,69.71,69.81,69.89, 70.13,70.36,70.40,70.45,71.42,71.65,75.16,121.5,126.9,129.7,131.8,140.8；HRMS calcd for C60H83Cl2N5O11S[M+2H]2+:576.7666；found:576.7652.
example 3
Cell activity experiments were performed separately for each ligand synthesized in example 2:
1. cell viability assay: luciferase reporter assays using NIH3T3 cells were performed to determine the activity of ligand compounds as SMO receptor antagonists. The signal was activated using 100nM SAG (Sellect, cat # S7779). The method comprises the following specific steps: cells (Clontech, cat # 631197) transgenic for the luciferase reporter gene NIH3T3 were cultured in 96-well plates to (6 x 10)5) One cell/well, then adding a concentration of 10000nM, 2000nM, 400nM, 80nM, 16nM, 3.2nM, 0.64 nM, 0.128nM, 0.0256nM, 0.00512nM of the ligand compound in gradient concentration for co-incubation at 37 deg.C for 1 hour, adding 100nM final concentration of activator SAG, and continuingCo-incubation was performed at 37 ℃ for 24 hours. Adding into
Figure BDA0001798453550000792
The Gli luciferase reporter level was determined using the fluorescein reporter system (Promega, cat # E2920) and using an Envision microplate reader (PerkinElmer). Three sets of data were run in parallel, curves were fitted according to the following formula and IC50 values for compounds were obtained.
Y＝Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))
Wherein X represents the concentration of the compound, Y represents the fluorescence reading measured by the microplate reader, Top represents the upper plateau value of the curve, and Bottom represents the lower plateau value of the curve. HillSlope represents the absolute value of the maximum slope of the curve.
2. The results of the experiment are shown in table 2:
TABLE 2
Figure BDA0001798453550000801
Figure BDA0001798453550000811
EC in cell Activity assay for some of the Bihead Compounds in the above Table50The values are superior to corresponding parent molecules, which indicates that the compounds can enhance the binding force and the cell activity by simultaneously binding the extracellular domain and the transmembrane domain of the smooth receptor, so the strategy can be applied to synthesizing high-activity small-molecule drugs targeting the smooth receptor.
Example 4
The reported crystal structures are more similar to the general synthetic drug molecule in that the ectodomain ligand is typically a steroid and the transmembrane domain ligand structure (FIG. 1B). In order to further study information such as the binding orientation of the small molecule ligand of the receptor co-crystal and the distance between the two binding domains (fig. 1A), and to confirm the role of the linker in the bipitch ligand, the relationship between its activity and linker length was examined by a series of bipitch molecules in which the linker length is different and the pharmacophore at both ends is used to bind to the smooth receptor. Specifically, linker length and activity information of OHC-SAG type double-headed molecules in which linker length was gradually changed are summarized in the following table:
TABLE 3
Figure BDA0001798453550000812
The relationship between linker length and activity is shown in FIG. 3. As can be seen from FIG. 3, the activity of the bipitch ligand is optimized when the linker length is appropriate. The principle can be explained by fig. 2: when the linker length is shorter than the distance between the binding sites, the two pharmacophores of the same bipitch molecule cannot bind to both sites of the SMO receptor simultaneously, and therefore cannot produce a synergistic effect and enhance activity (fig. 2 a); if the linker length coincides with the binding site spacing, within a certain length range, two pharmacophores can bind to two sites of the SMO receptor simultaneously, and due to the synergistic effect, the binding contributions are mutually enhanced, which is manifested as an enhanced activity (fig. 2 b); if the linker length is further increased, the activity is decreased because the entropy effect causes the synergistic effect to disappear and the two pharmacophores do not effectively enhance the activity (fig. 2 c).
In conclusion, the present invention effectively overcomes various disadvantages of the prior art and has high industrial utilization value.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.

Claims (14)

1. A smoothing receptor ligand, or an isomer prodrug, solvate, pharmaceutically acceptable salt thereof, having the structural formula:
A-linker-B
wherein A is an ectodomain ligand structure, and B is a transmembrane domain ligand structure;
linker is a linear, smooth receptor inactive subunit.
2. The smoothing receptor ligand of claim 1, wherein the ectodomain ligand structure is a steroid structure.
3. The smoothing receptor ligand of claim 1, wherein a is selected from the group consisting of:
Figure FDA0001798453540000011
wherein E is selected from H, -OH;
f is selected from linear C1-C20 aliphatic groups containing or not containing heteroatoms selected from N, S, P, O;
g is selected from linear C1-C20 alkyl or acyl with or without a heteroatom selected from N, S, P, O.
4. The smoothing receptor ligand of claim 1, wherein a has a structure selected from the group consisting of 20- (S) -hydroxycholesterol, 22- (S) -azacholesterol, cyclopamine, cholesterol, lithocholic acid, and 20- (S) -hydroxy-24-alkynylcholesterol.
5. The smoothing receptor ligand of claim 1, wherein a is selected from the group consisting of:
Figure FDA0001798453540000012
6. the smoothing receptor ligand of claim 1, wherein the transmembrane domain ligand structure is an amide or imine-like structure containing multiple aliphatic rings, nitrogen-containing aliphatic rings, benzene rings, nitrogen-containing aromatic ring systems.
7. The smoothing receptor ligand of claim 1, wherein B is selected from the group consisting of:
Figure FDA0001798453540000021
wherein J is selected from substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, substituted or unsubstituted pyridyl, substituted or unsubstituted cycloalkyl, wherein the substituents are each independently selected from alkyl, alkenyl, alkynyl, F, Cl, Br, I, nitro, amino, hydroxy, alkoxy, cycloalkyl, aryl, heteroaryl;
l is selected from hydrogen, alkyl and substituent groups are selected from-NR 'R' substituted or unsubstituted cycloalkyl, wherein R 'and R' are independently selected from C1-C6 alkyl;
m is selected from substituents selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, -CF3、-OCF3Substituted or unsubstituted aryl or heteroaryl of alkylsulfonyl.
8. The smoothing receptor ligand of claim 1, wherein the structure of B is selected from the group consisting of SAG, LY2940680, GDC0449, LDE225, SANT1, SANT 2.
9. The smoothing receptor ligand of claim 1, wherein B is selected from the group consisting of:
Figure FDA0001798453540000022
10. the smoothing receptor ligand of claim 1, wherein the linker is a polyethylene glycol oligomer having a triazole structure.
11. The smoothing receptor ligand of claim 1, wherein the linker has the formula:
Figure FDA0001798453540000031
wherein m and n are independently selected from integers between 0 and 7.
12. The smoothing receptor ligand of claim 1, wherein the smoothing receptor ligand is selected from the group consisting of:
Figure FDA0001798453540000032
Figure FDA0001798453540000041
Figure FDA0001798453540000051
Figure FDA0001798453540000061
Figure FDA0001798453540000071
Figure FDA0001798453540000081
Figure FDA0001798453540000091
Figure FDA0001798453540000101
13. use of the smoothing receptor ligand of any one of claims 1-10, or an isomer, prodrug, solvate, pharmaceutically acceptable salt thereof, for the preparation of a smoothing receptor agonist, inhibitor or antagonist.
14. A pharmaceutical composition comprising a smoothing receptor ligand according to any one of claims 1-10, or an isomer, prodrug, solvate, or pharmaceutically acceptable salt thereof.
CN201811066683.5A 2018-09-13 2018-09-13 Smooth receptor ligand Pending CN110894209A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811066683.5A CN110894209A (en) 2018-09-13 2018-09-13 Smooth receptor ligand

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811066683.5A CN110894209A (en) 2018-09-13 2018-09-13 Smooth receptor ligand

Publications (1)

Publication Number Publication Date
CN110894209A true CN110894209A (en) 2020-03-20

Family

ID=69785260

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811066683.5A Pending CN110894209A (en) 2018-09-13 2018-09-13 Smooth receptor ligand

Country Status (1)

Country Link
CN (1) CN110894209A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112209878A (en) * 2020-10-26 2021-01-12 上海科技大学 Cannabinoid receptor light-operated ligand and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027135A2 (en) * 1999-10-13 2001-04-19 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
CN106831718A (en) * 2016-12-30 2017-06-13 上海科技大学 Smoothened receptors part and its application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027135A2 (en) * 1999-10-13 2001-04-19 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
CN106831718A (en) * 2016-12-30 2017-06-13 上海科技大学 Smoothened receptors part and its application

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EAMON F. X. BYRNE 等: "Structural basis of Smoothened regulation by its extracellular domains", 《NATURE》 *
叶林涛: "开发化学小分子工具用于平滑受体的研究", 《中国科学院大学硕士学位论文》 *
张飞: "用于Smoothened受体研究的小分子工具开发", 《中国科学院上海生命科学研究院、上海科技大学博士后出站工作报告》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112209878A (en) * 2020-10-26 2021-01-12 上海科技大学 Cannabinoid receptor light-operated ligand and preparation method and application thereof

Similar Documents

Publication Publication Date Title
JP7266538B2 (en) Lactam compounds as FXR receptor agonists
KR102089234B1 (en) Pyridine derivatives as ASK1 inhibitors and methods for their preparation and use
EP3661921B1 (en) Selective inhibitors of nlrp3 inflammasome
JP7025432B2 (en) Pyran derivative as an inhibitor of CYP11A1 (cytochrome P450 monooxygenase 11A1)
KR100423899B1 (en) Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation
TWI659019B (en) Pyrazole amide derivative
CN112135612A (en) Amino acid compounds and methods of use
KR20190015275A (en) Piperidine as a Menin Inhibitor
WO2021027943A1 (en) Pyrimidinopyridazinone derivative and medical use thereof
CN114929706A (en) Inhibitors of KRAS G12C
US10336697B2 (en) Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors
WO2016112637A1 (en) Btk inhibitor
TW201623251A (en) Spirocyclic HAT inhibitors and methods for their use
OA12919A (en) Acetyl 2-hydroxy-1,3 diaminoalkanes.
JP6746613B2 (en) Urea derivative or its pharmacologically acceptable salt
CN101296914A (en) Derivative having PPAR agonistic activity
JP6526275B2 (en) SHIP 1 Modulators and Related Methods
CN101495463A (en) Seven-membered ring compound, production method thereof and pharmaceutical use thereof
CN111961034A (en) Compounds useful as RET kinase inhibitors and uses thereof
CN116964058A (en) KRAS G12D inhibitor and application thereof in medicine
WO2021098883A1 (en) Compound used as egfr kinase inhibitor and use thereof
WO2015006691A1 (en) Pro-drug forming compounds
JP2013067631A (en) New bicyclic angiotensin ii agonist
CN110894209A (en) Smooth receptor ligand
JP6200495B2 (en) α-Substituted glycinamide derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200320